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ABSTRACT
Background: Surrogate endpoints, i.e., intermediate endpoints intended to predict for 
patient-centered outcomes, are increasingly common. However, little is known about how 
surrogate evidence is handled in the context of health technology assessment (HTA). 
Objectives: (i) to map methodologies for the validation of surrogate endpoints and (ii) to 
determine their impact on acceptability of surrogates and coverage decisions made by HTA 
agencies.
Methods: We sought HTA reports where evaluation relied on a surrogate from eight HTA 
agencies. We extracted data on the methods applied for surrogate validation. We assessed the 
level of agreement between agencies and fitted mixed-effects logistic regression models to 
test the impact of validation approaches on the agency’s acceptability of the surrogate 
endpoint and their coverage recommendation.
Results: Of the 124 included reports, 61 (49%) discussed the level of evidence to support the 
relationship between the surrogate and the patient-centered endpoint, 27 (22%) reported a 
correlation coefficient/association measure, and 40 (32%) quantified the expected effect on 
the patient-centered outcome. Overall, the surrogate endpoint was deemed acceptable in 49 
(40%) reports (k-coefficient 0.10, p=0.004). Any consideration of the level of evidence was 
associated with accepting the surrogate endpoint as valid (odds ratio (OR) 4.60, 95% 
confidence interval (CI): 1.60 to 13.18, p=0.005). However, we did not find strong evidence 
of an association between accepting the surrogate endpoint and agency coverage 
recommendation (OR 0.71, CI: 0.23 to 2.20. p=0.55). 
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Conclusions: Handling of surrogate endpoint evidence in reports varied greatly across HTA 
agencies, with inconsistent consideration of the level of evidence and statistical validation. 
Our findings call for careful reconsideration of the issue of surrogacy and the need for 
harmonization of practices across international HTA agencies. 
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Background
In recent years, regulatory agencies, including the European Medicines Agency (EMA) and 
the Food and Drug Administration (FDA) in the United States, have increasingly approved 
drugs and biologics on the basis of surrogate endpoints (1). A surrogate endpoint is defined 
as a biomarker or physiological measure, laboratory test result, imaging result, or another 
replacement end point that is thought to capture the causal pathway through which the 
disease process affects the patient-centered outcomes (2).
When used as primary outcomes, surrogate endpoints enable clinical trials of smaller sample 
size, shorter duration, and lower cost than trials with a patient-centered primary endpoint (3). 
The uptake of surrogate endpoints in pivotal trials is typically associated with expedited drug 
review and accelerated approval programs resulting in market authorization based on less 
rigorous evidence, i.e., fewer and smaller studies, without an appropriate comparator, or 
single-arm studies (4). However, once licensed, patient access to these products typically 
depends on assessment by an health technology assessment (HTA) agency that informs  a 
country’s or region’s coverage of reimbursement decision. (5). Whilst regulatory bodies are 
primarily concerned with the efficacy-safety, HTA agencies seek to assess the long-term 
comparative effectiveness and economic consequences of health technologies, alongside 
other considerations such as equity, severity of disease, or unmet need. Recent research has 
shown that the  methodological guidelines of HTA agencies often take a conservative 
approach to the use of surrogate endpoints to support their coverage recommendations, for 
example by (a) expressing a preference for patient-relevant outcomes (such as mortality); (b) 
recommending that surrogate endpoints should only be used in situations where patient-
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relevant outcomes are not available or their evidence is limited, or (c) limiting use of 
surrogate outcomes to validated measures (6, 7). 
Four previous studies have investigated the impact of surrogate endpoints on HTA decisions. 
Two studies focused on cancer drugs (16, 17) two considered the range of technology 
appraisals undertaken by either National Institute of Health and Care Excellence (NICE) in 
United Kingdom or the Canadian Common Drug Review (18, 19). However, these previous 
studies did not assess HTA agencies approach to validation of the surrogate endpoints or how 
this related to their coverage recommendation. 
The objectives of this study were: (i) to map the methodological approaches for the validation 
of surrogate endpoints applied in reports across a sample of international HTA agencies and 
(ii) to assess how the consideration of the validity of the surrogate endpoints influences the 
coverage or reimbursement decisions made by these agencies.
Methods
Selection of HTA reports
We applied a two-step approach to the selection and inclusion of HTA reports in this study. 
First, we sought to identify health technologies and related HTA reports that involved the use 
of surrogate endpoints. We used the surrogate endpoint definition of the US National 
Institutes of Health i.e., a biomarker (or intermediate endpoint) intended to substitute for a 
clinical endpoint (20). We screened the guidance published by NICE between May 2013 and 
June 2018. All technology appraisal guidance, medical technologies guidance, and 
diagnostics guidance reports published in this timeframe were screened by one of the 
research team (BG) for inclusion on the basis that they included discussion of a surrogate 
endpoint. 
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Second, based on a  selected list of NICE evaluations (and reports), we then identified HTA 
evaluation reports for the same health technology and clinical indication from a further 
sample of six HTA agencies. These agencies included; Health Improvement Scotland 
(HIS)/Scottish Medicines Consortium (SMC) in Scotland, Haute Autorité de Santé (HAS) in 
France, Pharmaceutical Benefits Advisory Committee (PBAC) and Medical Services 
Advisory Committee (MSAC) in Australia, Canadian Agency for Drugs and Technologies in 
Health (CADTH) in Canada, Institut für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen (IQWiG)/ Gemeinsame Bundesausschuss (G-BA) in Germany, 
Zorginstituut Nederland (ZiN) in the Netherlands, and Országos Gyógyszerészeti és 
Élelmezés-egészségügyi Intézet (NIPN) in Hungary. These agencies span different 
geographical areas, include some of the most prominent HTA organizations worldwide, and 
are known to follow methodological guidelines that include consideration of surrogate 
endpoints with different levels of detail (7). Between August and September 2018, we sought 
all relevant reports from these agencies, irrespective of language and publication date.
Framework for assessment and validation of surrogate endpoints 
In the biostatistics literature several approaches have been discussed that would be identify 
when a biomarker is ‘likely to predict’ a patient-centered endpoint of interest (8). Most 
common methods are framed within the causal inference and meta-analytic paradigms (9, 
10). The two-stage meta-analytic approach developed by Buyse et al. requires demonstration 
of strong correlation between the surrogate and definitive endpoints (‘individual-level 
surrogacy’) as well as correlation of treatment effects on both endpoints (‘trial-level 
surrogacy’). Meta-analysis of individual patient data (IPD) remains the optimal approach 
because it enables the standardization of methods across IPD sets and robust analysis at both 
the patient and trial levels. However, because IPD meta-analyses are time and resource 
intensive, meta-analyses of outcome correlation or trial-level associations using aggregate 
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data are more often reported. Bayesian multivariate meta-analytic methods of estimation are 
increasingly used, as they take into account the correlation between the treatment effects on 
the surrogate and patient-centered outcomes in addition to the uncertainty in  the surrogate 
relationship (11).
A recent overview of HTA guidelines, identified only five HTA agencies provide detailed 
advice on the statistical methods that should be used for the validation of surrogate endpoints 
(7). These guidelines note the current lack of consensus on the minimum criteria to establish 
the validity of surrogates (7). Numerical values discussed as thresholds for acceptable 
surrogacy include a coefficient of determination R² ≥ 0.6 or 0.7 (12, 13), or a coefficient of 
correlation R ≥ 0.85 (14). 
In 2017, Ciani et al proposed a methodological framework for the incorporation and reporting 
of the use of surrogate endpoints in HTA (15). A three-step approach was recommended: (i) 
to establish the level of evidence available (i.e., whether the relationship between the putative 
surrogate endpoint and patient-centered endpoint of interest is supported by clinical 
plausibility, observational data or meta-analyses of multiple randomised controlled trials); (ii) 
to assess the strength of the association between the surrogate and patient-centered outcomes: 
observational association or treatment effect assessment (e.g., correlation coefficient at the 
individual and at the trial level); (iii) to quantify the expected effect on the patient-centered 
outcome given the observed effect on the surrogate endpoint. Table 1 elaborates this 3-stage 
methodological framework, illustrated with examples of good practice. 
Table 1 Methods for the validation of surrogate endpoints – 3 stage framework
Data extraction from reports
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We developed a structured extraction form for included HTA reports based on the above 
framework, previous studies (21), and the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist (22). We considered the following categories of 
information: general characteristics of the evaluation/report, characteristics of the health 
technology, and orphan status designation. Orphan designation is attributed to medicines that 
are intended to treatment, prevention or diagnosis of a rare disease (usually no more than 5 in 
10,000 in the relevant jurisdiction) that is life-threatening or chronically debilitating; that are 
unlikely to generate sufficient returns to justify the investment needed for the medicines’ 
development, and that provide a significant benefit in relation to the efficacy or safety of the 
treatment, prevention or diagnosis of the same condition (23, 24, 25).
We analysed characteristics of the included surrogate endpoint (i.e., source of evidence, 
justification for use, methods for validation, how surrogate endpoint was incorporated in 
economic modelling (if undertaken), and other considerations), how uncertainty was dealt 
with in relation to consideration of surrogate endpoint (including restricted coverage or price 
discounts), and final coverage/reimbursement recommendation. Following the three-step 
validation framework described above (15), we assessed:(1) the level of evidence available to 
support the surrogate-to-final outcome relationship (e.g. an individual patient data meta-
analysis of RCTs would represent the highest level of evidence); (2) whether the report 
discussed the association between surrogate and final outcome with a related metric (e.g. 
spearman’s ρ) given; and (3) whether the report discussed quantification of the expected 
treatment effect on the patient-centered endpoint based on the observed effect on the 
surrogate endpoint, either from previous evidence or based on the decision model in the 
report (Table 1). In addition, we assessed the level of acceptability of the surrogate endpoint. 
For example, “increase in total kidney volume correlates to growth in cyst volume and was 
considered to be an appropriate surrogate for disease progression” would be a statement that 
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indicates acceptability of total kidney volume as a surrogate by the appraisal committee. 
Finally, we investigated how the surrogate endpoint - was used in the development of the 
cost-effectiveness model and the reimbursement/coverage recommendation made. We 
recorded if finance-based (e.g., ‘Patient Access Schemes’ in the United Kingdom intended to 
provide the National Health Service with access to the technology based on confidential 
discount from list price) or performance-based risk-sharing arrangements (e.g., plans to track 
the performance of the product over a specified period of time so to inform the amount or 
level of reimbursement based on the health outcomes achieved) were agreed with the 
manufacturer (26). 
The data extraction form was piloted on three HTA reports (by OC, BG, RST). Following 
this pilot, information was extracted from each HTA report by one of the authors. Non-
English reports were data extracted by co-authors who were native or proficient speakers and 
translated into English. A random sample of the reports (n=36) was checked for accuracy of 
data extraction by another member of the team (either OC, BG or RT). 
Data analysis and synthesis
We used tables and descriptive statistics to summarise extracted data and enable comparison 
of information across agencies (for a given health technology) and within agencies (across 
HTA reports). Two key areas of results presentation are: (i) the methodological handling of 
surrogate endpoints in HTA reports and how this influences the acceptability of surrogate 
endpoints, and (ii) how surrogate endpoint validity influences the final 
reimbursement/coverage recommendation made by HTA agencies. In case of multiple 
evaluations made by an agency for the same technology, we considered the latest evaluation. 
Given that clinical evidence often accumulates after marketing authorization, we considered 
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this to be a conservative approach, i.e., looking at the highest evidence base for surrogate 
validation.
We determined the level of agreement between agencies in terms of acceptability of surrogate 
endpoint and final recommendations made using a generalization of the kappa coefficient for 
binary observations and multiple observers. We interpreted Kappa values as follows: values ≤ 
0 as indicating no agreement and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as 
moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement (27).
We collapsed categorical variables into binary responses (acceptable surrogate vs no/unclear; 
approved technology vs rejected/restricted), and we fitted univariable and multivariable 
mixed-effects logistic regression models to test: (1) the impact of level of evidence, reporting 
a metric of association, quantifying the expected effect on the patient-centered outcome, and 
orphan status, on the HTA agency’s acceptability of the surrogate endpoint; and (2) the 
impact of the acceptability of the surrogate endpoint (and previous variables) on the final 
coverage recommendations given by the HTA agency. We applied the standard two-tailed 
p<0.05 threshold for the interpretation of statistical significance of regression coefficients. 
We conducted all statistical analyses in Stata/SE 16.1.
Results
Description of health technologies under assessment and included reports
We screened a total of 291 HTA reports from NICE, of which 23 (8%) were included in the 
analysis. Among the 23 technologies assessed, 21 (91%) were pharmaceuticals and two (9%) 
were medical devices. Twelve (52%) technologies were used for an oncology indication, 
three (13%) for a cardiovascular indication, two (9%) for either endocrinology or nephrology 
indication, and the remainder spread across a variety of conditions (i.e., chronic hepatitis C, 
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biliary cholangitis, vitreomacular traction, pulmonary fibrosis). A summary of the 
technologies included is available in Table 2.
Table 2 Characteristics of health technologies and related HTA evaluation
The most frequently considered surrogate endpoint was progression-free survival and was 
used in the evaluation of seven (30%) technologies (Axitinib, two indications of Bortezomib, 
Brentuximab, Cobimetinib, Pertuzumab, Ribociclib), all intended for oncology indications. 
Major/complete cytogenetic response was used in four (17%) oncologic evaluations 
(Bosutinib, Dasatinib first and second line, Pertuzumab). Changes in low-density lipoprotein 
cholesterol levels were used in two (9%) technologies intended for dyslipidaemia 
(Alirocumab, Evolocumab). Other surrogate endpoints were either biomarkers (parathyroid 
hormone, testosterone level, prostate specific antigen, alkaline phosphatase, bilirubin, 
glycated haemoglobin, sustained virologic response), functional measurements (forced vital 
capacity, venous blood flow, change in total kidney volume), or measure of clinical response 
(e.g., proportion of patients with non-surgical resolution of focal vitreomacular traction). 
We identified a total of 124 reports across all eight HTA agencies matching these NICE 
appraisals (Figure 1). These reports included a total of 341 archived documents (including the 
reports, associated recommendations, appendices, and responses to consultation) that were 
obtained and screened for data extraction (see Supplementary Material). Four technologies 
(Alirocumab, Evolocumab, Pirfenidone, Ribociclib) were evaluated across all eight agencies. 
One technology (’the geko device, FirstKind Ltd) was only evaluated by NICE. The median 
number of evaluations per technology was five.
Figure 1 Flow diagram of HTA report selection 
How validation of surrogate endpoints is empirically addressed in HTA reports
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To investigate how the validation of putative surrogate endpoints was addressed in practice, 
each of the 124 unique reports was considered as a separate observation (Table 3). 
Table 3 Summary of characteristics of HTA reports
The level of evidence to establish the validity of the surrogate was clearly assessed in 61 
(49%) evaluations and not assessed in 57 (46%). In the other 6 reports this information was 
unclear (5%). Only 27 reports (22%) reported a measure of strength of association between 
the putative surrogate endpoint and the patient-relevant endpoint of interest and in the 
majority of the evaluations (97, 78%) there was no correlation metric reported. Forty (32%) 
evaluations quantified the predicted effect of the surrogate endpoint on the patient-centered 
outcome; the majority of reports did not (72, 58%) or failed not provide enough information 
(12, 10%) for us to judge whether this was actually done. The surrogate endpoints were 
overall deemed ‘acceptable’ in 49 reports (40%), ‘unacceptable’ in 23 (18%), with no clear 
statement on acceptability provided in the remaining 52 (42%) evaluations (Supplementary 
Table 1). 
Variation between agencies 
The level of depth and scrutiny applied by different agencies in relation to the validation of 
surrogate endpoints varied (Figure 2). NICE was the agency most likely to report on the level 
of evidence (22/23), strength of association (7/23) and quantification of effect (17/23) related 
to the validation of a putative surrogate endpoint. In contrast, HAS and NIPN were the 
agencies with the least level of information reported in terms of validation. 
Figure 2 Steps of the validation of surrogate endpoints performed by HTA agencies
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IQWiG appeared to apply a particularly strict approach with respect to the acceptability of 
surrogate endpoints, with no surrogate outcome explicitly deemed valid. Pairwise kappa 
coefficients revealed moderate to substantial (>0.40) agreement on the acceptability of the 
surrogate endpoint between NICE and SMC, and between PBAC and NIPN HTA. Overall, 
there was very low level of agreement across the eight agencies was 0.10 (p = 0.04) 
(Supplementary Table 2). 
Variation between health technologies 
High consistency in the acceptability was seen for cholesterol level used in the assessment of 
Alirocumab in hypercholesterolaemia (only IQWiG did not accept the validity of this 
putative surrogate endpoint (28)) (Supplementary Figure 1). Total kidney volume used in the 
assessment of Tolvaptan in autosomal dominant polycystic kidney disease was accepted in 5 
out 6 assessments (CADTH stated that the relationship between total kidney volume and 
clinically important end points ‘remains to be elucidated’ (29)). For other health 
technologies, conclusions about the validity of the surrogate endpoints were conflicting. For 
example, alkaline phosphatase and bilirubin were deemed as valid in the assessment of 
Obeticholic acid for primary biliary cholangitis by three agencies (NICE (30), SMC (31), 
CADTH (32)) and invalid by three agencies (HAS (33), IQWiG/G-BA (34), ZIN (35)). 
Level of evidence 
The acceptability of the putative surrogate measure should be based on the related level of 
evidence (see Table 1). This can be as low as expert opinion, as in the NICE HTA assessment 
of PFS of Brentuximab vedotin in CD30-positive Hodgkin lymphoma (36), or as high as 
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individual-patient data meta-analyses of RCTs, as seen in the evaluation of pathological 
complete response of Pertuzumab in HER2-+ breast cancer (37). However, a higher level of 
evidence did not always result in a positive opinion expressed by the committee in relation to 
the acceptability of the surrogate. For example, based on the CollaborativeTrials in 
Neoadjuvant Breast Cancer pooled individual-patient data meta-analysis, CADTH concluded 
(38) that there is insufficient evidence to support the validity of pathological complete 
response as a surrogate for long-term outcomes in breast cancer (39). In contrast, informed by 
clinicians’ opinion, NICE accepted PFS for Brentuximab vedotin in CD30-positive Hodgkin 
lymphoma (36).
Strength of association
Reports often discussed the concept of association or correlation between the two endpoints 
of interest but rarely reported an actual metric (e.g., R2, Spearman’s ρ correlation coefficient). 
For example, the Pirfenidone in idiopathic pulmonary fibrosis appraisal by NICE (40) cited 
one study showing that there is a moderate correlation between changes in percent predicted 
forced vital capacity and changes in a disease specific health-related quality of life measure 
(i.e., Spearman’s ρ correlation coefficient of -0.32). Lack of reporting of correlation metrics 
may reflect the difficult interpretation of these values, limited methods guidance, or 
presumed confidence in the validity of the surrogate. 
Quantification of effect on patient-relevant outcomes
Quantification of the expected treatment effect on the patient-centered outcome based on the 
observed effect on the surrogate endpoint was rarely reported. In some cases this 
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quantification was a risk equation based on previous longitudinal studies or registries in the 
same (or similar) therapy area. In the appraisal of Evolocumab in primary 
hypercholesterolaemia/mixed dyslipidaemia, treatment effects were modelled with published 
risk equations from the Framingham Heart Study and the UK REACH registry for 
cardiovascular disease patients (41). The surrogate threshold effect (STE) has been proposed 
as key metric to identify the minimum level of observed effect on the surrogate endpoint in 
order to predict a significant effect on the patient-centered outcome (42). However, STE was 
only reported by IQWIG report on Ribociclib in locally advanced or metastatic breast cancer 
(43). 
Use of surrogate endpoint evidence in cost-effectiveness models
For those reports that included a cost-effectiveness analysis, surrogate endpoints were usually 
a key input in the decision model. For example, annual change in total kidney volume was 
used as an intermediate step to model change in estimated glomerular filtration rate (eGFR) 
in the cost-effectiveness model of Tolvaptan in autosomal dominant polycystic kidney 
disease (44). Whilst quantification of the treatment effect on the final outcome based on the 
surrogate could be an output of the decision model, we did not find any examples of this 
across reports in this study. Despite a pivotal trial powered for a surrogate primary endpoint, 
the available cost-effectiveness models were developed using immature survival data from 
short-term studies extrapolated to obtain estimates of the full survival benefit (45, 46). 
Evidence around the validation of the primary surrogate endpoint could inform the choice of 
the methods for performing the extrapolation in economic models (e.g., how plausible the 
extrapolated portions are), (47) but we never encountered this across our sample of HTA 
reports.
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Whilst surrogate endpoints are generally assumed to replace for patient-relevant outcomes, 
such as overall survival, in cost-effectiveness models they may also be used to predict health 
related quality of life. For example, a key utility value was an assumed 0.04 increase in 
health-related quality of life for patients experiencing a sustained virologic response with the 
use of Ledipasvir–Sofosbuvir drug combination in chronic hepatitis C evaluation. (48) They 
may also be used to predict healthcare resource consumption/costs (e.g. progression free 
survival as a proxy for time on treatment with biologic Cobimetinib for the management of 
unresectable or metastatic melanoma) (49).
Multivariable regression analysis showed that reporting about the level of evidence 
supporting the relationship between the putative surrogate and the patient-centered endpoint 
of interest increased the probability of accepting the validity of the surrogate endpoints (odds 
ratio: 4.60, 95% CI: 1.60 to 13.18, p  = 0.005), regardless as to whether this evidence is 
biological, plausibility anecdotal, observational or experimental (Table 4). That these other 
elements are statistically significant in univariate regressions suggests that they are correlated 
with reporting of evidence. 
Table 4 Factors associated with surrogate acceptability and recommendation given
What impact does use of surrogate endpoints have on the recommendations given?
We were able to examine the recommendations based on 113 assessments (11 (9%) HTA 
recommendations given by NIPH were not publicly accessible) (Table 2). Pairwise kappa 
coefficients show at least modest (>0.20) agreement on the final recommendation given by 
IQWiG/G-BA and SMC and substantial (>0.60) agreement on the final recommendation 
given by IQWiG/G-BA and HAS. Overall, the level of agreement across the eight agencies 
was relatively low (0.18, p = 0.004) (Supplementary Table 3).
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For eight (6%) of the recommendations, orphan drug designation was associated with either 
full approval (n = 6) or restricted approval (n = 2). A patient access scheme was mandated in 
19 (16%) of the restricted recommendations by NICE and SMC, with risk-sharing 
agreements being required in 3 (2%) of these restricted recommendations. In 10 (8%) of the 
restricted recommendations, a price reduction was required. Lack of benefit, high uncertainty 
on outcomes, or insufficient evidence on the relationship between the surrogate and patient-
relevant outcomes was explicitly cited in 13 (11%) rejections. In contrast, 6 (5%) approval 
recommendations were made despite stated uncertainty in clinical or cost-effectiveness 
evidence (Supplementary Table 4). 
With the exception of orphan status (odds ratio 8.61, 95% 1.03 - 72.94, p = 0.047), none of 
the other factors were predictive of the final coverage recommendation (Table 4).
Discussion
In this study we mapped the methods used in 124 surrogate endpoint-based HTA 
evaluations/reports on 23 different health technologies across eight HTA agencies. Based on 
a previously proposed three-step framework for the validation of surrogate outcomes (15), we 
found that 61 (49%) of reports discussed the level of evidence to support the relationship 
between the surrogate endpoint and the patient-centered outcome based on a IPD meta-
analyses of randomised controlled trials in the relevant indication. Only 27 (22%) evaluations 
reported a correlation coefficient or other association measure. When available, these 
associations were usually below recommended thresholds for acceptability of surrogate (i.e., 
the lower limit of the 95% confidence interval for R  0·85 recommended by IQWiG) (50). 
Forty (32%) reports quantified the expected effect on the patient-centered outcome given the 
observed effect on the surrogate outcome. A clear statement around the acceptability of the 
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surrogate endpoint was provided in 49 (40%) reports, whilst 23 (19%) rejected the validity of 
the proposed surrogate endpoint. Our regression models showed that searching for evidence 
of the relationship between the surrogate and patient-centered outcome was a predictor of the 
HTA agency’s acceptance of the surrogate endpoint but did not show any significant effect 
for the other steps in the validation process. 
Among the 113 assessments with a policy recommendation, 32 (28%) technologies were 
fully approved, 20 (18%) were rejected, and 61 (54%) received restricted approval. To handle 
the decision uncertainty as the result of the use surrogate endpoints, HTA agencies often used 
conditional approval based n price discount agreements (including patient access and risk-
sharing schemes with evidence development), restricted indications, or applied more 
permissive evaluation frameworks (such as orphan technology designation, end-of-life 
treatment, or specialist coverage programmes, such as the Cancer Drugs Fund in the UK). For 
example, when evaluating Bosutinib, all HTA agencies had access to results of the main 
study that reported major cytogenetic response and immature overall survival data. IQWiG 
approved Bosutinib as an orphan medicine despite concluding that major cytogenetic 
response and overall survival was limited. Scottish Medicine Consortium also found ‘high 
uncertainty around the survival estimate’ but still approved Bosutinib as part of the ultra-
orphan process. Whilst the reimbursement of drugs authorized with orphan designation may 
vary across Europe, orphan status is usually a policy imperative that commits HTA agencies 
to recommend even without evidence of additional benefit (51). We found weak evidence 
that the acceptability of the surrogate endpoint was associated with the final coverage 
decision made by HTA agencies. 
We found considerable variability in the level of scrutiny applied with respect to the 
surrogacy issue across HTA agencies. This variability is in part explained by differences in 
the methodological guidelines followed by the HTA agencies (7). Different expertise 
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available to the committee, different level of reporting, or different interpretations of the 
definition of surrogate endpoints may also play a role. Some surrogate endpoints, especially 
so-called intermediate endpoints (e.g., progression free survival, disease free survival, event 
free survival), may be considered not to require validation by HTA agencies as that they have 
been already accepted by a regulatory body for marketing authorization. In several cases, 
HTA agencies quoted EMA or FDA approval documents to support their acceptance of the 
validity of a surrogate endpoint. However, it is important to recognise that the mandate of 
regulators is not the same as HTA organizations (19). The underlying evidence for the 
accepted surrogate endpoints for regulatory review may be weak or missing (52, 53). As a 
lifecycle evaluation to healthcare technologies has become more widespread, regulatory 
agencies have gained statutory authority to order post-marketing studies, typically in the case 
of approvals based on uncertain evidence. However, only 1 in 10 of new drug indications 
approved by the US FDA on the basis of surrogate endpoints have been shown to have at 
least one post-approval trial validating the use of the surrogate or demonstrating improved 
overall survival (54, 55, 56).
Surrogate endpoint evidence impacts both the assessment of clinical and cost-effectiveness of 
a health technology (7). However, we found limited consideration in the economic elements 
of the HTA reports included in this study. For example, some cost-effectiveness models were 
based on extrapolations of immature survival data from short-term studies rather than use of  
validated  primary surrogate endpoint data. Furthermore, there was little use of biomarkers or 
intermediate endpoints as replacements for either health-related quality of life or healthcare 
resource consumption/costs. . 
Limitations
































































                                                                             
21
Our analyses were limited to consideration of publicly available information and reporting 
detail varied greatly between agencies. As we based our initial selection of technologies on a 
text search for surrogacy terms of NICE reports , we many have excluded report/technologies 
that using surrogate endpoint evidence. We cannot exclude the possibility that consideration 
of surrogacy issues occurred during HTA committee meetings but that these observations 
were not reported in public documents. Some of the non-English reports were not double 
screened due to lack of language expertise across the co-authors. Although we only identified 
only two non-drug technologies in on our sample, we believe that the findings of report apply 
equally to such technologies, including medical devices 
Conclusions 
We found that the handling of surrogate endpoint evidence varied greatly across HTA reports 
and agencies, with inconsistent consideration of level of evidence and statistical validation. 
Consideration of the level of evidence supporting the relationship between the surrogate 
endpoint and patient-centre outcome increased the likelihood of acceptability of a surrogate 
endpoint. However, we did not find strong evidence supporting an association between 
accepting the surrogate  and the coverage recommendation made about the treatment. Claims 
of surrogate validity need to be considered contextually, given that the relationship between 
surrogate endpoint and patient-relevant outcome is typically treatment- and indication- 
specific. 
HTA evaluation reports often refer to regulatory (FDA or EMA) statements about the 
acceptability of surrogate endpoints. However, regulators are more focused on safety and 
shorter-term efficacy, and registration trials are often specifically designed to answer these 
questions. Given that HTA agencies focus on a longer-term perspective and seek to assess 
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clinical effectiveness and cost-effectiveness, their considerations on the acceptability of 
surrogate endpoints may differ to those of regulators (57).  
Our findings demonstrate the need for further consideration of the issue of surrogacy and for 
harmonization of practices between regulatory and HTA agencies and across international 
jurisdictions.
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Figure 1 Flow diagram of HTA report selection
Note: TA = technology appraisal; DG = diagnostic guidance; MTG = medical technologies 
guidance
CADTH = Canadian Agency for Drugs and Technologies in Health; HAS = Haute Autorité de 
Santé; HIS/SMC = Health Improvement Scotland / Scottish Medicines Consortium; IQWiG/G-BA 
= Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen / Gemeinsame 
Bundesausschuss; NIPN = Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; 
PBAC/MSAC = Pharmaceutical Benefits Advisory Committee / Medical Services Advisory 
Committee; ZIN = Zorginstituut Nederland
































































































































































































































































































































































































































































































Note: CADTH = Canadian Agency for Drugs and Technologies in Health; HAS = Haute Autorité de Santé (France); HIS/SMC = Health Improvement 
Scotland / Scottish Medicines Consortium; IQWiG/G-BA = Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen / Gemeinsame 
Bundesausschuss (Germany); PBAC = Pharmaceutical Benefits Advisory Committee (Australia); ZIN = Zorginstituut Nederland (the Netherlands)
































































Table 1 Methods for the validation of surrogate endpoints – 3 stage framework
Level of evidence Strength of the association Quantification of the expected effect on the 
patient-centered outcome
Level 1: Randomised 
controlled trials showing 
that treatment changes in 
the surrogate are 
associated with treatment 









Meta-analysis of individual 
patient-data / aggregate-data 
from randomised controlled 
trials that have assessed both 
the surrogate and patient-
centered endpoints
With trial/country/center as 
the analysis unit
Preferably within the same 
indication and treatment class
For individual-level 
surrogacy
As above or even single large 
randomised controlled trial 
/observational studies that 
have assessed both the 





understanding of the 
disease process 
demonstrating the 
biological plausibility of 
relation between
surrogate and final 
outcome
For trial-level surrogacy
 Coefficient of correlation (Kendall’s tau, 
Spearman’s rho, Pearson within-study 
correlations from multivariate meta-
analyses)
 Coefficient of determination from 
weighted/unweighted adjusted/unadjusted 
linear regression of treatment effects on 
endpoints/copula models 
For individual-level surrogacy
 Coefficient of correlation (Kendall’s tau, 
Spearman’s rho, Pearson)
 Coefficient of determination from 
weighted/unweighted adjusted/unadjusted 
linear regression of treatment effects on 
endpoints/copula models
 Hazard Ratio from Cox 
regressions/Bayesian hierarchical analysis
For trial-level surrogacy
 Prediction based on the estimated regression 
equation for the trial-level surrogacy and 
observed effect on the surrogate endpoint
 Intercept, slope and conditional variance of the 
linear model of the relationship between the 
treatment effects on the surrogate endpoint and 
the effects on the final outcome based on 
aggregate data Bayesian multivariate meta-
analyses.
 Surrogate threshold effect (STE), the minimum 
treatment effect on the surrogate necessary to 
predict a non-zero effect on the patient-centered 
outcomes using the 95% prediction limits of the 
regression line
































































Table 2 Summary of characteristics of HTA reports
Characteristics
Total number of HTA 
reports (N = 124)
Drugs 122 98%
Medical device 2 2%
HTA Agencies
NICE 23 19%
HIS/ SMC 20 16%
HAS 20 16%
PBAC/ MSAC 15 12%
CADTH 13 10%









Infectious Disease 7 6%
Ophthalmology 6 5%
Gastroenterology 6 5%
Orphan status 8 6%
Surrogate validation
Surrogate accepted (YES) 49 40%
Level of evidence assessed (YES) 61 49%
Strength of association provided (YES) 27 22%





No recommendation 11 9%
CADTH = Canadian Agency for Drugs and Technologies in Health; HAS = Haute Autorité de Santé; HIS/ 
SMC = Health Improvement Scotland / Scottish Medicines Consortium; IQWiG/ G-BA = Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen/ Gemeinsame Bundesausschuss; NICE = National Institute for 
Health and Care Excellence; NIPN = Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; PBAC/ 
MSAC = Pharmaceutical Benefits Advisory Committee/ Medical Services Advisory Committee; ZiN = 
Zorginstituut Nederland. 
































































Table 3 Characteristics of health technologies and related HTA evaluation 
N Technology Indication Clinical area















































primary hypercholesterolaemia and 
mixed dyslipidaemia Cardiovascular
Low-density lipoprotein cholesterol, 
Total cholesterol to high-density 
lipoprotein cholesterol ratio 
[incidence of cardiovascular events]         8
2 Axitinib
advanced renal cell carcinoma after 
failure of prior systemic treatment Cancer
Progression-free survival [overall 
survival]    1   -  7
3 Bortezomib
previously untreated mantle cell 
lymphoma
Cancer Progression-free survival [overall 
survival]    - - - - - 3
4 Bortezomib
induction therapy in multiple myeloma 
before high-dose chemotherapy and 
autologous stem cell transplantation
Cancer Response rate
Progression-free survival [overall 
survival]      - - - 5
5 Bosutinib
previously treated chronic myeloid 
leukaemia
Cancer Major cytogenetic response [overall 
survival]    -   -  6
6
Brentuximab 
vedotin CD30-positive Hodgkin lymphoma
Cancer Progression-free survival [overall 





unresectable or metastatic BRAF V600 
mutation-positive melanoma
Cancer
Progression-free survival [overall 
survival]       -  7
8 Dasatinib
untreated chronic myeloid leukaemia 
(1st line)
Cancer Complete cytogenetic response 
Major molecular response [overall 
survival] 1  - 1 - - - - 3
9 Dasatinib
imatinib-resistant or intolerant chronic 
myeloid leukaemia (2nd line)
Cancer Complete cytogenetic response
Major molecular response [overall 
survival] 1  1  - -  - 5
10 Degarelix
advanced hormone-dependent prostate 
cancer
Cancer Prostate specific antigen
Testosterone levels [overall 
 1 1 1 - -   6
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N Technology Indication Clinical area















































11 Etelcalcetide secondary hyperparathyroidism Endocrinology
Parathyroid hormone level 
[incidence of death, fractures or 
cardiovascular events]    - -  -  5
12 Evolocumab
primary hypercholesterolaemia and 
mixed dyslipidaemia Cardiovascular
Low-density lipoprotein cholesterol 
[incidence of cardiovascular events]   1 1     8
13 Imatinib
adjuvant treatment of gastrointestinal 
stromal tumours Cancer
Recurrence-free survival [overall 
survival]  1 - 1 - - - - 3
14
Ledipasvir–
sofosbuvir chronic hepatitis C
Infectious 
diseases
Sustained virologic response at 12 
Weeks [sustained virologic response 
at 24 weeks]  1  - 1    7
15 Lesinurad
chronic hyperuricaemia in people with 
gout Nephrology Serum uric level [overall survival]  -  - - - - - 2
16 Obeticholic acid primary biliary cholangitis
Gastroenterolog
y
Alkaline phosphatase and bilirubin 
levels at 12-months [overall 
survival]    -    - 6
17 Ocriplasmin vitreomacular traction Ophthalmology
% of patients with non-surgical 
resolution of focal vitreomacular 
traction [vision impairment]   1 1   - - 6
18 Pertuzumab
neoadjuvant treatment of HER2-
positive breast cancer Cancer
Pathological complete response
Invasive disease-free survival
Progression-free survival [overall 
survival]    1 1  -  7
19 Pirfenidone idiopathic pulmonary fibrosis Pulmonology Forced vital capacity [overall 
survival, health-related quality of 
   1 1    8
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N Technology Indication Clinical area



















































previously untreated, hormone receptor-
positive, HER2-negative, locally 
advanced or metastatic breast cancer Cancer
Progression-free survival [overall 
survival]    1     8
21 Tolvaptan
autosomal dominant polycystic kidney 
disease Nephrology
Change in total kidney volume from 
baseline [progression to end-stage 





management of blood glucose levels in 
type 1 diabetes Endocrinology
Glycated haemoglobin [incidence of 
complications of diabetes] 1 - 1 -2 - - - - 2
23 The Geko device
reducing the risk of venous 
thromboembolism Cardiovascular
Increase in blood flow [risk of 
venous thromboembolism]  - - -2 - - - - 1
    HTA by technology 23 20 20 15 13 13 9 11 124
Note: 1multiple evaluations available; 2 reports sought from MSAC; 3 One European Network of HTA (EUnetHTA) report identified 
https://www.eunethta.eu/the-joint-assessment-on-continuous-glucose-monitoring-cgm-real-time-and-flash-glucose-monitoring-fgm-as-personal-
standalone-systems-in-patients-with-diabetes-mellitus-treated-with-insuli/  = approved for reimbursement;  = restricted reimbursement (either 
restricted prescription or subject to a price change);  = rejected.
CADTH = Canadian Agency for Drugs and Technologies in Health; HAS = Haute Autorité de Santé; HIS/ SMC = Health Improvement Scotland / 
Scottish Medicines Consortium; IQWiG/ G-BA = Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen/ Gemeinsame Bundesausschuss; 
NICE = National Institute for Health and Care Excellence; NIPN = Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet; PBAC/ MSAC = 
Pharmaceutical Benefits Advisory Committee/ Medical Services Advisory Committee; ZiN = Zorginstituut Nederland.
































































Table 4 Factors associated with surrogate acceptability and recommendation given
Multivariate regression analysis* Univariate regression analysis* 
Factors associated with 
acceptability of surrogate endpoint
Odds ratios (95%CI) [p value] Odds ratios (95%CI) [p value] 
Level of evidence assessed 4.60 (1.60 -13.18) [p  = 0.005] 5.51 (2.42 - 12.55) [p<0.001]
Strength of association provided 1.23 (0.40 - 3.74) [p  = 0.72] 2.69 (1.04 - 6.97) [p = 0.041] 
Quantification of effect provided 1.17 (0.38 - 3.61) [p = 0.78] 3.52 (1.43 - 8.65) [p = 0.006]  
Orphan status 0.52 (0.81 – 3.39) [p = 0.50] 0.38 (0.06 - 2.36) [p = 0.30]  
Factors associated with positive 
recommendation
Acceptability of surrogate endpoint 0.71 (0.23 - 2.20) [p = 0.55] 0.52 (0.19 - 1.46) [p = 0.21]
Level of evidence assessed 0.32 (0.07 - 1.37) [p = 0.12] 0.40 (0.15 - 1.09) [p = 0.07]
Strength of association provided 2.30 (0.51 - 10.45) [p = 0.28] 1.42 (0.43 - 4.66) [p = 0.57]
Quantification of effect provided 1.12 (0.27 - 4.74) [p = 0.87] 0.57 (0.20 - 1.63) [p = 0.29]
Orphan status 8.61 (1.03 - 72.94) [p = 0.047] 11.38 (1.55 - 83.58) [p = 0.02] 
*from mixed-effect logistic regression with clustering at the level of the health technology. OR>1 indicates higher odds of the surrogate deemed acceptable or technology 
receiving positive recommendation 

































































Links to documents analysed1
1. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
National Institute for Health and Care Excellence (NICE): https://www.nice.org.uk/guidance/ta393
Health Improvement Scotland (HIS)/ Scottish Medicines Consortium (SMC): 
https://www.scottishmedicines.org.uk/media/1228/alirocumab_praluent_final_july_2016_amended_040816_for_website.pdf
Pharmaceutical Benefits Advisory Committee (PBAC), Medical Services Advisory Committee (MSAC): 
http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017-11/alirocumab-psd-november-2017
Canadian Agency for Drugs and Technologies in Health (CADTH): https://www.cadth.ca/alirocumab
Haute Autorité de Santé (HAS): https://www.has-sante.fr/portail/jcms/c_2629896/en/praluent-alirocumab-lipid-lowering-agent-anti-pcsk9
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)/ Gemeinsame Bundesausschuss (G-BA): https://www.g-
ba.de/bewertungsverfahren/nutzenbewertung/199/
Zorginstituut Nederland (ZiN): https://www.zorginstituutnederland.nl/publicaties/rapport/2016/03/30/alirocumab-praluent-bij-primaire-
hypercholesterolemie
2. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
NICE: https://www.nice.org.uk/guidance/ta333
HIS/SMC: https://www.scottishmedicines.org.uk/media/1284/axitinib_inlyta_resubmission_final_october_2013_amended_011113.pdf
1 Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (NIPN) documents are not publicly available
















































































5. Bosutinib for previously treated chronic myeloid leukaemia 



































































































































































10. Degarelix for treating advanced hormone-dependent prostate cancer 















































































12. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE: https://www.nice.org.uk/guidance/ta394
HIS/SMC: https://www.scottishmedicines.org.uk/media/1701/evolocumab__repatha__resubmission_final_jan_2017_for_website.pdf





























































































































































15. Lesinurad for treating chronic hyperuricaemia in people with gout
NICE: https://www.nice.org.uk/guidance/ta506
HAS: https://www.has-sante.fr/portail/jcms/c_2854458/en/zurampic-lesinurad-uricosuric
16. Obeticholic acid (OCA) [Ocaliva®] for primary biliary cirrhosis (PBC)– 2nd line in combination with ursodeoxycholic acid in adults with an 
inadequate response to ursodeoxycholic acid or 1st line as monotherapy in adults unable to tolerate ursodeoxycholic acid
NICE: https://www.nice.org.uk/guidance/ta443
HIS/SMC: https://www.scottishmedicines.org.uk/media/2055/obeticholic_acid_ocaliva_final_may_2017_amended_170517_for_website.pdf



































































































































































20. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor positive, HER2-negative, locally advanced or metastatic 
breast cancer


















































































































































22. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo 




23. The geko device for reducing the risk of venous thromboembolism
NICE: https://www.nice.org.uk/guidance/mtg19
































































Supplementary Figure 1 Validity of surrogate endpoints by health technologies under evaluation
































































Supplementary Table 1 Validation of surrogate endpoints in HTA reports – detailed data extraction
Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
1. Alirocumab & hypercholesterolaemia: HDL-cholesterol 
NICE Yes Yes 
(Level I)
Meta-analysis of RCTs of 
LDL-C vs CV mortality1 
No
(No metric of association 
reported)
Yes
By assuming a log-linear 
relationship between LDL-C 
levels and cardiovascular 
events, the company 
estimated the risk reduction 
for cardiovascular mortality 
as rate ratios (RRs): 0.64 per 
1.0 mmol/l reduction in LDL-
C rate (95% CI 0.40 to 1.04) 
and 0.64 for myocardial 
infarction (95% CI 0.43 to 
0.96).
Meta-analysis of RCTs 
included mix of statin and 
PCSK9 inhibitor trials 
[1].
Markov model with 12 
states applied 
SMC Yes Yes
(Level I - Meta-analysis 
of RCTs of LDL-C vs CV 
mortality)
No
(No metric of association 
reported)
Unclear
(The model effect was 
worked through using LDL-C 
as a surrogate outcome 
measure linked to 
cardiovascular events, where 
reducing LDL-C is predicted 
Meta-analysis of RCTs 
included mix of statin and 
PCSK9 inhibitor trials 





































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
to reduce CV events in the 
future)
PBAC Yes
prior decisions by PBAC 
in lipid modifying 
therapy have historically 
accepted models using 
TC:HDL rather than 
LDL-c although the 
relationship between this 




(Level I - Analysis of two 
RCTs IPD) 
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported) 
The submission instead used 
change in TC:HDL 
cholesterol ratio based on 
post-hoc analyses from two 
trials (ODYSSEY COMBO 
II and ALTERNATIVE), 
transformed to cardiovascular 
outcomes in the economic 
model.
Used change in TC:HDL 
cholesterol ratio (rather 
than LDL-C level)




were derived from the 
secondary prevention 
Framingham risk equation 
for a composite CHD 
event (D’Agostino 2000 
[2]) using TC:HDL ratios 
adjusted for relative 
treatment effects
HAS Yes Yes
(Level I - Meta-analysis 
of RCTs of LDL-C vs CV 
mortality) 
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported)
Meta-analysis of RCTs 
included statin trials only 
(Baigent et al. 2010 [3])
Markov model, 12 health 
states, lifetime horizon 
(90 years)
CADTH Yes Yes No Yes Meta-analysis of RCTs 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
surrogate was considered 
as "widely accepted"
(Level I - Meta-analysis 
of RCTs of LDL-C vs CV 
mortality) 
 
(No metric of association 
reported)
(No quantified association 
reported)
Each 1 mmol/L reduction in 
LDL‐C produces a greater 
risk reduction in Navarese et 
al.’s meta‐analysis than in the 
CTTC meta‐analysis, which 
biases the results in favour of 
alirocumab.
included mix of statin and 
PCSK9 inhibitor trials 





The relationship between 
reduction in LDL‐C 
levels and risk reduction 
in CV events was derived 
from meta‐analyses of 
clinical trials that 
included lipid‐based and 
clinical outcomes.
Markov model with 
lifetime horizon (66 years 
on average); 12 health 
states
IQWIG/G-BA No
It is a laboratory value 
that is not considered per 
se as a patient-relevant 
Yes
(No level of evidence 
reported)
No
(No metric of association 
reported)
No





































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
endpoint, but as a 
surrogate parameter.
Information on the 
grounds for presenting 
the surrogate endpoint 
was not provided in the 
dossier.
ZIN Yes
Reference to EMA 
guidance on lipid 
disorders to justify the 




(No metric of association 
reported)
No
(No quantified association 
reported)
alirocumab was clustered 
with evolocumab (i.e. 
similar effectiveness and 
therefore an assessment 
of the cost-effectiveness 
is no longer required
NIPN HTA Yes 











(No metric of association 
reported)
Unclear
(No quantified association 
reported)
The company's model 
consisted of 12 mutually 
exclusive health state
2. Axitinib & advanced renal cell carcinoma: progression-free survival
NICE Yes
Reference to a previous 
NICE evaluation
Yes 
(Level I – Meta-analysis 
of RCTs of PFS vs OS) 
Yes 
(One study reported the 
results of a meta-analysis 
which showed a strong 
correlation (0.69) 
Yes
(Results suggested that a 1-
month difference in disease 
progression was associated 
with a 1.4-month difference 
3-state Markov model 
Different parametric 
distributions were used to 
extrapolate the OS and 
PFS data. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
between PFS and OS) in OS, but this quantified 
association was not used in 
the model)
Meta-analysis of RCTs of 
PFS vs OS in mRcc 
(Delea et al. 2012 [4], 
Heng et al. 2011 [5])
Tumour shrinkage also 
considered as surrogate 
end point but could not be 
validated (using the 
Prentice criteria 
developed for validating 
surrogate end points)
SMC Unclear No
(No level of evidence 
reported)
No




distributions were used to 
extrapolate the overall 
survival and progression-free 
survival data)
3-state Markov model 
CADTH Yes 
PFS is a surrogate 
outcome for overall 
survival in patients with 
advanced RCC who 
receive targeted therapies.
Yes
(Level I – II Meta-
analysis of RCTs of PFS 
vs OS in mRcc and an 
association between PFS 
and overall survival has 
been reported based on 
observational data.)
Yes
(An association between 
PFS and overall survival 
has been reported based 
on observational data)
No




Meta-analysis of RCTs of 
PFS vs OS in mRcc 
(Heng et al. [5])
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?





(No metric of association 
reported)
No





NIPN HTA Unclear No
(None reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
PBAC 2013 – 
2014 
No
The PBAC agreed with 
the ESC that the 
submission did not 
adequately support the 





(No metric of association 
reported)
Unclear





(No metric of association 
reported)
Unclear
(No quantified association 
reported)
3. Bortezomib for previously untreated mantle cell lymphoma: progression free survival
NICE Yes
The use of PFS as a 
surrogate for OS is 
supported be available 
literature
Yes 
(Level II – III A 
relationship between 
progression and OS was 
found in one abstract 
Yes
(Improvements in 3-year 
EFS/PFS are highly 
correlated with 
improvements in 5-year 
Yes 
(The company modelled 
survival using progression as 
a surrogate marker for overall 
survival)
The model included 5 
states: progression-free 
survival from first-line 
treatment; progressed 
from first-line treatment; 
progression-free survival 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
(Amin et al. 2014 [6]) and 
confirmed by UK 
clinicians) 
OS in aggressive NHL) from second-line 
treatment; progressed 
from second-line 
treatment; and death. 
Survival was extrapolated 
using a log-logistic model 
from progression data.
SMC Yes Yes 
(Unclear level)
Whilst this is a limitation 
of the clinical data, the 
company has supported 
this approach through a 
literature review showing 
published evidence of an 
association between PFS 
and OS in MCL
Yes
Whilst this is a limitation 
of the clinical data, the 
company has supported 
this approach through a 
literature review showing 
published evidence of an 
association between PFS 
and OS in MCL
Yes 
(Hence in the base case, 
survival estimates were based 
on PFS with OS for 
progressed patients assumed 
to be the same regardless of 
treatment arm, and 
extrapolated using the best 
fitting exponential function.)
Markov model, 5 states
Modest impacts on the 
ICER from uncertainty 
associated with varying 
the PFS and survival 
outcomes estimated
HAS Unclear 
The overall survival data 
are not mature so far, it is 
therefore difficult to fully 
appreciate the clinical 





(No metric of association 
reported)
No
(No quantified association 
reported)
No Economic evaluation
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
4. Bortezomib for induction therapy in multiple myeloma: PFS or response rate
NICE Yes
The ERG clinical expert 
agreed that response rate 
at induction predicts 
progression-free survival 
and overall survival. 
However, the ERG stated 
that other surrogate 
outcomes, such as post-
stem cell transplant 
response rate, may offer a 




(Level II - to model long-
term survival based on 
the post-induction 
response rates, the 
manufacturer extracted 
overall survival data from 
the MRC Myeloma VII 
trial because overall 
survival data from the 
PETHEMA trial were 
considered immature. For 
a scenario analysis, the 
manufacturer also used 
long-term survival data 
from the IFM90 trial from 
1996)
No
(No metric of association 
reported)
Yes 
(The model was based on 
response rate, and the 
relationship between 
response rate and overall 
survival was quantified using 
long-term survival data from 




The primary outcome of 
response rate is a 
surrogate outcome
Reference to EMA 
European Public 




[…] a good induction 
response is reported to be 
correlated with improved 




dependent on response was 
estimated using 5 year 
median OS data from the 
SCT [stem cell 
transplantation] arm of a 
published MRC study of SCT 
A Markov model 
structure was used in 
which treatment naïve 
patients receive induction 
therapy for up to 6 cycles 
and was designed to 
isolate the effect of 
response to treatment on 
survival outcomes. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
Bortezomib versus standard 
chemotherapy (Child et al. 
2003 [7])) 
PBAC No
Evaluation based on OS 
data from latest trials 
(VISTA)
Unclear No
(No metric of association 
reported)
No







(No metric of association 
reported)
No
(No quantified association 
reported)
Pre-existing model
While the clinical inputs 
used in the model are not 
ideal, they do appear 
reasonable.
HAS No
Evaluation based on OS 
data from latest
Unclear No
(No metric of association 
reported)
No




5. Bosutinib for previously treated chronic myeloid leukaemia: cytogenetic or molecular response
NICE Yes
Reference to the 
European Leukaemia Net 
guidelines 
The committee accepted 
that there is a relationship 
Yes 
(Level II – Jabbour et al. 
2009)
No
(No metric of association 
reported)
No





whether the relationship 
from a study that had 
assessed imatinib 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
between major 
cytogenetic response and 
overall survival 
escalation for CML 
(Jabbour 2009 [8]) could 
plausibly apply to 
bosutinib taken third line
SMC Unclear No 
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
OS was estimated as the sum 
of time on bosutinib 
treatment plus the anticipated 




Overall survival in the 
CP, AP and BP models 
was calculated through 
extrapolation and fitting 
parametric curves directly 
to the pivotal study data 
from the data snapshot
IQWIG/G-BA No
Cytogenic response and 
molecular response 
proposed as surrogates 
but not accepted
No 
(No level of evidence 
reported)
No
(No metric of association 
reported)
No





NIPN HTA Unclear No 
(No level of evidence 
reported)
No
(No metric of association 
reported)
No




HAS Unclear No 
(No level of evidence 
No
(No metric of association 
No
(No quantified association 
No economic model 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?




(Improvement in major 
cytogenetic response 
which is an acceptable 
surrogate for overall 
survival, 1- and 2- year 
progression-free survival 
rates, a manageable 
toxicity profile, and 
notable improvements in 
quality of life)
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No




6. Brentuximab vedotin & CD30-positive Hodgkin lymphoma: progression-free survival 
NICE Yes Yes 
(Expert opinion)
However, the clinical 
experts suggested that 
patients whose disease 
has not progressed after 2 
years are unlikely to 
relapse, and gains in 
progression-free survival 
would be a good predictor 
of overall survival 
No
(No metric of association 
reported)
No
(The committee agreed that 
assuming a 1:1 relationship 
between progression-free 
survival and overall survival 
was optimistic, but that it was 
reasonable to assume that an 
extension to progression-free 
survival would lead to some 
extension in overall survival.)
The committee also noted 
that the outcomes 
presented included the 
anti-tumour effect of 
brentuximab vedotin 
measured as response 
rate, which is less 
clinically relevant than 
progression-free survival 
and overall survival.
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
extensions in this 
population.
SMC No
(OS was taken from a 
published observational 
cohort study with the data 
adjusted to reflect the 
differences in baseline 
prognosis vis-a-vis the 
pivotal trial)
Unclear No
(No metric of association 
reported)
No
(No quantified association 
reported)
OS data was used in the 
end 
PBAC Yes
The pre-PBAC response 
contended that PFS is the 
most appropriate measure 
of efficacy to inform 
decision-making in this 
context as it is objectively 
assessed and captured 
both response and 
duration of response.
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported)
The cost utility analysis 
used a partitioned 
survival model (PSM) 
with two health states, 
progression-free and 
progressive disease. This 
did not reflect the clinical 
management algorithm, in 
which patients received 
several lines of therapy
HAS No Unclear No
(No metric of association 
reported)
No
(No quantified association 
reported)
OS data was used





No Yes No No Cost calculation
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
PFS and EFS could not 
be considered because 
insufficient evidence was 
provided for their 
validation
(Considered but unclear 
level) 
(No metric of association 
reported)
(No quantified association 
reported)
7. Cobimetinib & unresectable or metastatic melanoma: progression-free survival 
NICE Yes
Such PFS was used as a 
surrogate for time on 
treatment. 
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No






IQWIG sees this point as 
surrogate, but no 
justifications for 
Surrogates were delivered 
by the pharmaceutical 
firm
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No





PFS and response rate 
was considered as a 
patient relevant endpoint 
by pharmaceutical firm
NIPN HTA Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No





(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
PBAC Unclear No No No Cost-minimisation 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
(No level of evidence 
reported)
(No metric of association 
reported)





(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(PFS and OS data was used 
directly from the coBRIM 
trial and parametric survival 
models were used to 
extrapolate beyond the trial 
duration)
Partitioned-survival
No mention of surrogacy
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
8. Dasatinib & chronic myeloid leukemia (1st line): Complete Cytogenetic Response (CCyR) & Major Molecular Response (MMR)
NICE 2016 Yes
The committee concluded 
that the available 
evidence suggests that 
dasatinib and nilotinib 
provided superior clinical 
benefit, as measured by 
surrogate outcome 
measures, to standard-
dose imatinib in the first-
line treatment chronic-
Yes 
(Level II - a mixture of 
longer-term randomised 
and observational studies 
of imatinib only) 
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported)
The committee considered 
the assessment group's 
analysis of short-term 
surrogate response markers 
as predictors of longer-term 
patient-relevant outcomes.
As part of Cancer Drugs 
Fund partial 
reconsideration of NICE 
technology appraisal 
guidance 251 a cost-
minimisation analysis of 
dasatinib compared with 




































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
phase CML.
The committee accepted 
that the results of the 
analysis on imatinib-
treated patients, could be 
potentially applied to 
people receiving dasatinib 
or nilotinib.
NICE 2012 Yes 
Committee 
accepted…that people 
with either a complete 
cytogenetic response or 
major molecular response 




(Level II - The committee 
noted the poor quality of 
the evidence base with 
non-comparative studies, 
short treatment duration 
and use of surrogate 
outcomes to predict 
overall survival)
Yes
(No metric of association 
reported)
(BMS comments to DSU 
The use of surrogate 
outcomes in CML) It is 
proposed that the DSU 
update the report to 
reflect the wealth of 
evidence supporting a 
correlation between 
surrogate outcomes and 
survival in CML.
Yes 
(In the surrogate survival 
approach the overall survival 
was estimated using a 
surrogate relationship based 
on major molecular response 
or complete cytogenetic 
response at 12 months)
Cumulative survival 
approach and surrogate 
survival approach 
DSU states "relationship 




The committee explicitly 
considers cCCyR at 12 
months a valid surrogate 
Yes 
(Level II - Cytogenetic 
response evaluated in an 
interim analysis at 12 
Yes
(No metric of association 
reported)
Yes
(PFS and OS data up to 60 
months were available from 
A ‘time in state’ model 
was used consisting of 3 
health states: chronic 
phase (pre-progression), 
accelerated phase/blast 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
for PFS relying on EMA 
European Public 
Assessment Report 
month was used as 
surrogate primary 
endpoint when Glivec 
(Imatinib) was approved 
in first line treatment of 
CML (IRIS). In later 
analysis of the IRIS trial 
it was documented that 
CCyR at one year is
predictive for PFS [...] 
MMR could have been 
acceptable as a primary 
endpoint as it is a more 
sensitive way of 
measuring residual 
disease, and the previous 
protocol assistance 
recommended MMR as a 
secondary endpoint.[...]"
Response to tyrosine 
kinase inhibitors is the 
most important prognostic 
factor, and optimal 
response (cytogenetic 
and/or molecular 
response) is considered to 
be associated with the 
best long-term outcome, 
with a duration of life 
comparable with that of 
the general population.
the DASISION study and 
used in the model to derive 
pooled estimates of survival 




PBAC 2011 No No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No mention of surrogacy
PBAC 2016 No
The PBAC accepted that 
although dasatinib is 
superior to imatinib 400 
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
A trial-based economic 
evaluation was presented, 
based on the direct 
randomised trial (Study 
056). 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
mg daily based on CCyR, 
the Committee did not 
accept that this predicts 
superiority for 
progression free survival 
or overall survival.
It is uncertain whether the 
increase in CCyR (a 
surrogate outcome) found for 
dasatinib versus imatinib 400 
mg, without a difference in 
MCyR, would result in an 
improvement in final 
outcomes, PFS and OS.
The submission did not 
provide an assessment of 
what could be considered a 
minimally clinically 
important difference in either 
cCCyR or CCyR.
A stepped analysis was 
presented in which health 
outcomes were first 
presented as additional 
patients with a cCCyR 
within 13 months (Step 
1), additional time with 
cCCyR (Step 2) and then 
as quality-adjusted life 
years gained (Step 3)
9. Dasatinib & chronic myeloid leukemia (imatinib-resistant or intolerant): Cytogenetic, Molecular & Hematologic Response 
NICE 2016 Yes Yes 
(Level II - The committee 
noted that the clinical 
trials available were non-
comparative, of short 
duration and had used 
surrogate outcomes to 
predict overall survival. 
The committee noted the 
poor quality of the 
evidence base.)
No 
(No metric of association 
reported)
Yes
(In the surrogate survival 
approach, overall survival 
was estimated using a 
surrogate relationship based 
on major molecular response 
or complete cytogenetic 
response at 12 months.)
NICE 2016 Yes Yes No Yes In the absence of 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
Report by the 
Decision 
Support Unit
(Level II - The AG 
concluded that there is 
evidence suggesting that 
people who experience 
either a complete 
cytogenetic response or 
major molecular response 
following 12 months of 
treatment on imatinib 
have better long-term 
outcomes (up to 7 years) 
overall survival and 
progression-free survival 
than people who do not 
respond at 12-month 
followup.)
(No metric of association 
reported)
(In the surrogate survival 
approach, overall survival 
was estimated using a 
surrogate relationship based 
on major molecular response 
or complete cytogenetic 
response at 12 months.)
evidence for dasatinib and 
nilotinib, the AG 
considered that the same
relationship could be 
potentially applied to 
these treatments.
NICE 2011 Yes 
Reference to EMA 
marketing authorization 
of imatinib (the 
relationship between CR 
and survival is 
sufficiently strong to 
support the use of CR, in 
particular, as a surrogate 
measure of survival)
Yes 
(Level II - (BMS) As 
noted in the ELN 
guideline (Baccarani et al 
2009 [9]) and Marin et al 
(2008) [10], complete 
cytogenetic response is 
the most important 
response-related 
prognostic factor since 
Yes 
(No metric of association 
reported)
(Novartis) CCyR is the 
first main goal of 
treatment and that, as 
highlighted in the IRIS 
trial, there is a clear 
correlation between 
Unclear
(No quantified association 
reported)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
Marin et al. (2008) 
concluded that at 12 
months, the only 
independent predictors 
for PFS were: (1) being in 
CCyR (complete 
cytogenetic response)... 
and (2) prior loss of 
CCyR …; At 18 months, 
the only independent 
predictor for PFS was 
being in CCyR. 
Furthermore, the 
achievement of MMR 
(major molecular 
response) at 12 or 18 
months failed to confer 
any benefit in 5-year PFS 
or OS) 
achievement of CCyR, 
overall survival and PFS. 
There is also increasing 
evidence that MMR itself 
correlates with overall 
survival and progression 
free survival.
SMC Unclear Unclear No 
(No metric of association 
reported)
No
(No quantified association 
reported)
The sources of the clinical 
data included the CA180034 
and CA180035 studies, 
which were used to model 
In terms of model 
structure, for patients 
initiated in CP and AP, 
the model consisted of 
three health states: pre 
progression, post-
progression and death. 
For patients who were 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
PFS and OS curves for the 
following response 
categories: complete 
response, partial response 
and failure.
initiated in BP, a post-
progression state was not 
modeled and patients 
could either remain in BP 
or transition to death. 
Utilities were also 
presented separately for 
responders and non-
responders within each 
health state.
PBAC Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
A modelled economic 
evaluation was presented 
based on the key trial 
(imatinib resistant in 
chronic phase CML).
No mention of surrogacy
HAS 2007 - 
2008
Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No mention of surrogacy
ZIN Yes 
This includes a 
relationship between 
response, progression and 
overall survival.
Yes 
(Level II - Transitions in 
the model were based on 
one published study)
Yes
(Long-term response data 
and the data confirming 
the association response – 
progression-free survival-
Yes
(The model is driven by the 
assumption that response 
rates are predictive for 
disease progression from the 
A Markov model 
including states based on 
the different phases of the 
disease (chronic, 
acceleration, blast) and 
death. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
overall survival in 
patients treated with 
dasatinib is currently 
lacking. There are only 
studies available 
investigating the efficacy 
and effectiveness of 
imatinib (i.e. the 
comparator treatment) in 
chronic myeloid 
leukaemia patients)
chronic to the acceleration 
and blast phase. This 
association is based on 
studies investigating the 
efficacy and effectiveness of 
imatinib (i.e. the comparator 
treatment) in chronic myeloid 
leukaemia patients.)
10. Degarelix & advanced hormone-dependent prostate cancer: testosterone levels, PSA & PFS
NICE No
The clinical experts stated 
that, although PSA 
progression is a good 
indicator of treatment 
response, caution should 
be taken when using it as 




(Level II  - several studies 
demonstrated some level 
of association between 
post-therapy falls in PSA 
or PSA relapse and long-
term prognosis, but none 
confirmed PSA could be 
used as surrogate end 
points. Data from 1078 
patients with hormone-
sensitive prostate cancer 
included in the Southwest 
Oncology Group trial 
9346 showed that PSA 
Yes 
(Data from the 
bicalutamide trial 
programme showed a 
modest correlation 
between time to PSA 
progression and 
objectively confirmed 
progression (Tombal et al. 
2010 [11]) 
Yes
(The relationship between 
PSA progression and overall 
survival was assumed in the 
model)
There was no robust evidence 
to support any overall 
survival benefit for degarelix 
compared with LHRH 
agonists and concluded that 
no overall survival benefit for 
degarelix compared with 
LHRH agonists should have 
been assumed in the model.
The cost-effectiveness 
results were most 
sensitive to […] the 
assumption that PSA 
progression had an effect 
on overall survival in 
patients with metastatic 
disease.
The manufacturer 
assumed that there was a 
relationship between PSA 
progression and overall 
survival and applied an 
increased risk of mortality 
to the model for those 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
progression (increase of 
25% from nadir and an 
absolute increase of 2 or 
5 ng/ml) predicts overall 
survival and may 
therefore be a suitable 
end point for studies in 
similar settings)
patients with metastatic 
disease. 
SMC Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No




The PBAC accepted that 
use of testosterone levels 
as a surrogate outcome 
was reasonable
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No





(No level of evidence 
reported)
No
(No metric of association 
reported)
No




(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No modelling conducted
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
ZIN Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No modelling approach 
was used (i.e. no 
assessment of the cost-
effectiveness of degarelix 
took place). 
11. Etelcalcetide & secondary hyperparathyroidism: parathyroid hormone levels
NICE Unclear 
The committee was 
uncertain of the 
generalisability of this 
specific surrogate 
outcome to long-term 
outcomes such as 





(No metric of association 
reported)
Yes
(The committee was aware 
that the company's approach 
assumed that the rate of 
achieving a 30% reduction in 
parathyroid hormone level 
would translate into a directly 
proportional effect on 
mortality, fractures, 
cardiovascular events and the 
need for parathyroidectomy)
4-health states Markov 
model 
The committee agreed 
with the ERG that 
Evaluation of Cinacalcet 
Hydrochloride Therapy to 
Lower Cardiovascular 
Events (EVOLVE) trial 
was the best available 
source of evidence for the 
long-term effects of 
calcimimetics, but it had 
concerns about the 
robustness of the 
estimates.
SMC Unclear
Although the EMA 
considered the surrogate 




(No metric of association 
reported)
No
(No quantified association 
reported)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
studies to be clinically 
relevant, the lack of direct 
health outcome data 
should be noted as a 
source of uncertainty
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No




(No level of evidence 
reported)
No
(No metric of association 
reported)
No





NIPN HTA Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
Markov-cohort
12. Evolocumab & primary hypercholesterolaemia and mixed dyslipidaemia: LDL-c levels
NICE Yes 
The clinical experts 
generally considered 
LDL-C to be a reasonable 
surrogate for future CV 
events, although they 
Yes 
(Level I - The committee 
was aware that the 
reduction in CV events 
with statins has been 
confirmed by many large 
Yes 
(No metric of association 
reported)
The ongoing Further 
cardiovascular OUtcomes 
Yes 
(Treatment effect modelled 
with published risk equations 
from the Framingham Heart 
Study for patients without 
CVD, and the REACH 
Markov model, 24 states
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
advised that this 
relationship was uncertain 
when the LDL-C 
concentration at baseline 
is low (below 2.0 mmol/ 
litre).
RCTs (CTT meta-
analysis [12]). By 
contrast, adding other 
lipid modifying 
substances to statins has 
not consistently been 
shown to further decrease 
CV events.) 
Research with PCSK9 
Inhibition in subjects with 
Elevated Risk 
(FOURIER) RCT will 
test whether LDL-C is a 
valid surrogate for CV 
outcomes for 
evolocumab, which it 
considered to be a key 
area of uncertainty in the 
current evidence 
(CADTH refers one year 
later to the results of this 
trial)
registry for patients with 
CVD. The company 
estimated calibration 
(adjustment) factors from an 
analysis of data from the 
Clinical Practice Research 
Datalink (CPRD) and 




reduction is considered to 
be a surrogate marker for 
cardiovascular risk 
reduction, the main 
evidence is with statin 
therapy 
Yes 
(Level II - there is as yet 
no robust evidence for 
evolocumab)
No
(No metric of association 
reported)
Yes
(Treatment effects on CV 
risks were modelled based on 
data from a "UK data 
registry”)
Markov model
PBAC Unclear Yes 
(Level II - Prior event 
multiplier based on 
observational data from 
No
(No metric of association 
reported)
Yes
(Transition probabilities were 
derived from the composite 
annual event rates 
Five core health state
- MI (no history of IS)
- MI (history of IS)
- IS (with or without 
history of MI)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
UK CPRD GOLD 
database. Distribution of 
events (including fatal 
events) also based on 
observational data from 
the UK CPRD GOLD 
database)
(Framingham risk equations 
with familial 
hypercholesterolaemia 
multiplier and prior recent 
event multiplier within 12 
months of an event) adjusted 
for the composite relative 
event rate associated with the 
reduction in LDL from 
treatment, adjusted for the 







CADTH questions the 
use of LDL-c to estimate 
CV risk in the model, 
while there is trial data 
with clinically relevant 
outcomes (Sabatine et al. 
2017, FOURIER [13])
Yes 
(Level I - The treatment 
effect of evolocumab on 
CV events and mortality 
was estimated based on 
the association between 
reduction of LDL-C and 
CV risk and mortality 
observed with statins 
from the Cholesterol 
Treatment Trialists’ 
Collaboration meta-
analysis (Baigent 2010 
[3]).)
Yes 
(The FOURIER trial 
failed to demonstrate a 
strong correlation 
between LDL-C levels 
and clinical outcomes, 
making extrapolation 
from other trials or to 
other populations based 
on LDL-C levels 
unreliable)
Yes
(FOURIER trial CV event 
RR per mmol/L LDL-C 
reduction was markedly 
lower than predicted; the 
clinical expert indicated that 
only a 15% to 20% CV risk 
reduction was observed in the 
trial, while a 50% CV risk 
reduction was predicted 
based on LDL-C lowering 
(under the assumption of a 
similar relationship as 
observed with statins). The 
Cost-utility analysis 
The following health 
states were used in the 
model: established 
cardiovascular (CV) 
disease, acute coronary 
syndrome (ACS), 
ischemic stroke (IS), heart 
failure (HF), post-ACS, 
post-IS, post-HF, CV 
death, and non-CV death. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
observed RRs from 
FOURIER were used in the 
CADTH Common Drug 
Review (CDR) reanalysis 
(with difficulty, as the model 
was not designed to use this 
data)
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
IQWIG/G-BA Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No






Reference to EMA 
Guidance on lipid 
disorders to justify the 
surrogate outcomes
Yes 
(Level II - The model is 
driven by the assumption 
that lowering LDL-C 
leads to a reduction in the 
risk of cardiovascular 
events. This association is 
based on research with 
statin treatment. It is 
assumed that the same 
No
(No metric of association 
reported)
Yes
(The risk of cardiovascular 
events is determined by an 
epidemiological prediction 
model that is linked to LDL 
concentration.
(..) For the first event, the 
risks are determined on the 
basis of the Framingham 
study and for second and 
Markov model 
The difference in 
effectiveness between the 
two treatment arms is 
determined by the 
difference in the 
reduction of the LDL 
cholesterol level. The 
treatment effect translates 
into a difference in the 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
association applies to 
treatment with other 
lipid-lowering substances, 
such as evolucumab and 
ezetimibe)
subsequent events, based on 
the European study REACH. 
Both studies present a 
prediction model with 
different risk factors 
(predictors).
risk of cardiovascular 
events and death. 
NIPN HTA Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
Markov-model with 
health states: non CVD 
events, ECVD, ACS, IS, 
HF, Post-ACS, Post-IS, 
Post-HF, death
13. Imatinib & gastrointestinal stromal tumours: recurrence-free survival
NICE Unclear
NICE questioned why the 
manufaturer's submission 
included recurrence-free 
survival, when other 





(No metric of association 
reported)
Yes 
(The model predicts the long 
term outcome for RFS 
(recurrence-free survival), 
based on the trial results 
reported to date. Therefore 
recurrence, or the avoidance 
of it, is the key determinant 
of overall survival)
Markov model
SMC 2002 - 
2010
Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported)
Markov model
Clinical data for the 
model were based on data 
from the pivotal study but 
a modelling approach was 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
necessary to extrapolate 
the short-term data over 
the lifetime duration of 
the analysis.
PBAC 2009 - 
2011
Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
Unclear
(2009: The PBAC noted that 
the main driver of the 
economic model was the 
assumption that most of the 
increase in recurrence-free 
survival with adjuvant 
imatinib treatment would be 
maintained as an overall 
survival gain.)
2011: In an attempt to 
address the PBAC’s 
concerns, the submission 
presented a series of 
scenarios)
Markov model
14. Ledipasvir–sofosbuvir & chronic hepatitis C: Sustained Virologic Response 12 Weeks
NICE Yes 
Surrogate for surrogate - 
The ERG commented that 
using SVR12 was 
appropriate because there 
Yes
(Level II - The company 
chose transition 
probabilities for disease 
progression from several 
Yes 
(No metric of association 
reported)
The ERG commented that 
Yes
(Transition probabilities from 
the non-cirrhotic to cirrhotic 
health state varied according 
to disease stage and treatment 
Markov state-transition 
with 9 states, according to 
disease stage and 
treatment response. 
The same model structure 
was used for all people 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
is a high correlation 
between SVR12 and 
SVR24. However, it 
noted that SVR4 is not a 
suitable surrogate end 
point for cure because 
there is a chance of 
relapse between 4 and 12 
weeks.
publications used in 
recent NICE technology 
appraisals of treatments 
for HCV (Thompson et 
al. 2008 [14]; Cardoso et 
al. 2010 [15]; Fattovich et 
al. 1997 [16]; 
Grishchenko et al. 2009 
[17]; Hartwell et al. 2011 
[18]; Shepherd et al. 2007 
[19]; Siebert et al. 2005 
[20]))
using SVR12 was 
appropriate because there 
is a high correlation 
between SVR12 and 
SVR24
response, age and genotype 
according to published 
literature.)
irrespective of HCV 
genotype or treatment 
experience. 
SMC Yes 
SVR (assumed to have 
permanently cleared virus 




(No metric of association 
reported)
Yes
(The key clinical data in the 
model related to the SVR 
rates and adverse events on 
treatment. These were taken 
from naive indirect 
comparisons of the relevant 
treatments.)
Markov model
The model covered states 




liver transplant and post-
liver transplant. 
A key utility value was an 
assumed 0.04 increase in 
quality of life for patients 
experiencing an SVR, 
based on a published 
study. 
CADTH Yes Yes Yes Yes Markov cohort model, 
where patients are located 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
(A review using 
individual patient data 
from 15 phase 2 and 3 
studies (N = 13,599 
participants), in which the 
majority were patients 
with G1 (N = 11,730), 
suggests that SVR12 is a 
reliable surrogate for 
SVR24. The authors 
suggest that SVR12 may 
become a new definition 
for SVR for regulatory 
approval.
Higher utility values 
associated with SVR)
(In 2013, the FDA 
published a paper that 
sought to determine the 
predictive value of 
SVR12 as a surrogate for 
SVR24. The authors 
reviewed data submitted 
to the FDA (2002 to 
2011) from 15 phase 2 
and 3 studies that 
included various 
treatment durations of 
pegylated interferon (Peg-
IFN) alfa-2a, Peg-IFN 
alfa-2b, albinterferon 
alfa-2b, telaprevir, and 
boceprevir.)
(The positive predictive 
value between SVR12 
and SVR24 was 98.3% 
and the negative 
predictive value was 
98.8%. They also stated 
that these conclusions 
should be applied with 
caution to direct-acting 
antiviral (DAA)–only 
regimens, considering 
that they were based on 
data from regimens 
containing interferon plus 
ribavirin (RBV))
(The authors also performed 
a Bayesian random-effects 
meta-regression of the 
proportion with SVR12 or 
SVR24, controlling for the 
type of Peg-IFN. The authors 
concluded that SVR12 was 
5% to 6% higher than 
SVR24, although the credible 
intervals overlapped in the 
conventional meta-analysis, 
and in the Bayesian meta-
regression, the credible 
intervals included the null 
value (SVR12 versus SVR24 
relative risk 1.13; 95% 
credible interval, 0.99 to 
1.26))
in one of nine states (2 
deal with non-cirrhotic 
disease (chronic hepatitis 
C [CHC] non-cirrhotic 
and sustained virologic 
response [SVR] non-
cirrhotic); 3 states deal 
with cirrhotic disease 
(compensated cirrhosis, 
decompensated cirrhosis, 
and SVR cirrhotic); 3 





transplant). The final state 
is death.
HAS Yes 





(No metric of association 
reported)
SVR12 was well 
correlated with SVR24
No




Formal validation of the 
Yes 
(Level II - The 
Yes
(No metric of association 
No




































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
SVR as a surrogate 
endpoint within the 
framework of correlation-
related studies did not 
exist.
Since the pharmaceutical 
firm has not provided any 
new data to validate the 
SVR, the endpoint is still 
considered unquantifiable 
in terms of its magnitude
pharmaceutical firm 
presents results on the 
surrogate endpoint SVR 
as part of the benefit 
assessment and describes 
why, in his view, the 
SVR and quantifiable 
results as a surrogate for 
disease-related morbidity 
are justified. However, 
observational studies 
would indicate the use of 
SVR as a validated 
surrogate parameter for 
disease progression. 
Since the pharmaceutical 
firm has not provided any 
new data to validate the 
SVR, the endpoint is still 
considered unquantifiable 
in terms of its magnitude 






The patient relevance 
would be determined by 
the clear correlation 
between morbidity, 
mortality and the 
presence of HCV and was 
also be confirmed by the 
G-BA. Formal validation 
of the SVR as a surrogate 
endpoint within the 
framework of correlation-
related studies did not 
exist, because of ethical 
reasons and due to the 
several years of 
corresponding studies. 
reported)
ZIN Yes Yes Yes No No modelling approach 
was used (i.e. no 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
ZIN refers to the EMA 
guideline that considers 
SVR24 as the most 
relevant outcome in 
clinical studies since it is 
predictive for long-term 
cure. Due to the strong 
correlation between 
SVR24 and SVR12, the 
latter is also accepted.
 (Level II - ZIN refers to 
EMA conclusion; SVR24 
predictive for long-term 
cure)
(No metric of association 
reported)
Due to the strong 
correlation (98-99%) 
between SVR24 and 
SVR12, the latter is also 
accepted.
(No quantified association 
reported for the relation of 
SVR12 to long-term cure. 
There is a proportion 
mentioned for SVR24 and 
SVR12)
assessment of the cost-
effectiveness).
NIPN HTA Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
Unclear
(No quantified association 
reported)
Markov model 10 health 
states:









• Post-liver transplant 
• CHC-attributed death 
• Background mortality
15. Lesinurad & gout: serum uric levels
NICE Yes Yes 
(Level II – III The 
No
(No metric of association 
Yes 
(The company used the 
Semi-markov with 10 
health states
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
company presented the 
results of 7 observational 
studies it had identified in 
a systematic review, 
which suggested that 
people with a higher 
serum uric acid level had 
a shorter life expectancy 
than people with a lower 
serum uric acid 
level…They argued that 
high serum uric acid 
levels increase the 
immune response and 
inflammation, and that 
chronic inflammation is 
associated with further 
comorbidities, such as 
cardiovascular risk, in 
other conditions like 
rheumatoid arthritis)
reported) results from 1 of the 7 
observational studies by 
Stack et al. 2013 [21] to 
estimate the life expectancy 
and the magnitude of the 
benefit of lowering serum 
uric acid levels. Based on this 
study, the company modelled 
that, above a serum uric acid 
level of 5 mg/100 ml (300 
micromol/litre), mortality 
risk increased by 16% for 
every 1 mg/100 ml increase 
in serum uric acid level)
The committee was 
concerned that this study 
was a national survey of 
the US general 
population, which did not 
reflect the population in 
this appraisal because 
only 2.7% of people had 
gout and it included 
people with normal serum 
uric acid levels
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No economic model
16. Obeticholic acid & primary biliary cholangitis: alkaline phosphatase (ALP) and bilirubin
NICE Yes Yes No Yes The first part of the model 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
The clinical experts 
confirmed that these 
biochemical markers are 
appropriate and validated 
surrogate outcomes for 
PBC.
(Level II - This primary 
source of evidence quoted 





and the disease 
course/prognosis of PBC 
(Lammers et al. 2014 
[22])
(No metric of association 
reported)
(No quantified association 
reported)
The cost effectiveness case 
was driven around trial based 
difference in surrogate 
outcomes
(referred to as the 
‘biomarker component’) 
captures the surrogate 
outcomes of ALP and 
bilirubin biomarkers in 
three different health 
states based on the 
expected risk of disease 
progression.
SMC Yes 
Obeticholic acid is 
expected to delay disease 
progression, delay / avoid 




(No metric of association 
reported)
Patient and clinician 
engagement (PACE) 
participants highlighted 
high correlation between 
surrogate biochemical 
markers and long-term 
clinical outcomes.
Yes
(No quantified association 
reported)
Patients entered the model in 
either a PBC moderate or 
high risk of liver disease 
health state defined by 
surrogate biochemistry 
markers of ALP and 
bilirubin, with the high risk 
state also covering 
compensated cirrhosis.
CADTH Yes Yes No Yes The model health states 
covered: the primary 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
The key surrogates used, 
ALP and bilirubin, appear 
to be accepted surrogate 
biomarkers in PBC, and 
any elevation above the 
ULN is considered likely 
to be clinically relevant
(Unclear - The POISE 
[23] study’s primary end 
point is a validated 
outcome and has 
previously been shown to 
be predictive of the 
natural history of PBC)
(No metric of association 
reported)
(No quantified association 
reported)
biliary cholangitis (PBC)–
specific liver disease 
component, representing 
the progression of PBC 
based on alkaline 
phosphatase (ALP) and 
bilirubin biomarkers 
(three health states), and 
the liver disease clinical 
outcome component 
(seven health states), 
which is entered once 





On the basis of available 
data, the impact on 
morbidity, mortality or 
quality of life is not yet 
demonstrated. According 
to HAS, the association 
of several biomarkers in a 
single intermediate 
outcome is debatable, 
since the relationship is 
Yes 
(Level II - The transition 
probabilities for the AOC 
+ AUDC cohort were 
obtained from the 
decompensation rate 
observed in UCDA 
responders according to 
Harms et al. (2015) [24]. 
Transition probabilities 
for the non-treatment 
No
(No metric of association 
reported)
Yes
(No quantified association 
reported)
Same model as for NICE, 
with French specific data.
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
not demonstrated cohort were calibrated 
from data published by 
the international groups 
Global PBC Study Group 
and UK PBC, as well as 
ad-hoc analyses of 
individual POISE data 
using GLOBE and UK 
risk scores.)
IQWIG/G-BA No
The data sources do not 
provide sufficient 
validation of the 
surrogate endpoint, so 
that this argument cannot 
be followed.
Yes 
(Level II - The 
pharmaceutical firm 
argues that both 
parameters have been 
validated in large PBC 
registers ("UK-PBC" and 
"GLOBE"). Lammers et 
al. 2015 [25] Meta-
analysis of individual 
patient data (N=4.845) 
from Cohort studies from 
15 centres for the 
determination of the 
association of ALP and 
bilirubin with liver 
transplant and death. The 
evidence is too thin to be 
Yes
(No metric of association 
reported)
Correlation is sufficient to 
derive a prediction score. 
In addition, the endpoint 
for which the prediction 
score is directed is quite 
heterogeneous 
(esophageal varices, 
laboratory values, death). 
It cannot say exactly for 
which part of the 
combined endpoint which 
laboratory values allow 
predictive statements.
No
(No quantified association 
reported)
Carbone et al. 2015 [26] 
Derivation of a prediction 
score that does not 
necessarily have to "prove" 
the validity of laboratory 
parameters as surrogate 
endpoints. There does not 




Contrary to the 
assessment of the 
pharmaceutical firm, the 
primary combined 
efficacy endpoint - 
defined as the 
dichotomous combined 
alkaline phosphatase 
(ALP) endpoint < 1.67 x 
ULN with simultaneous 
reduction of the ALP 
value by at least 15 % and 
a total bilirubin<= ULN - 
is classified as an 
unvalidated surrogate 
parameter. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
tested by an established 
surrogate endpoint, as no 
meta-analytical results 
from RCTs are available. 
To evaluate the effects 
both on the surrogate and 
on the endpoints. Momah 
et al. 2011: No 
comparison with placebo 
or an active/Missing 
comparison to placebo or 
an active Comparator. 
Display of different 
dosages of UDCA. Not 
suitable to represent the 












The EMA and FDA 
raised objections to this 




overall survival) had not 
been established
Yes 
(Level II - Manufacturer 
introduced a, not 
previously used, 
surrogate outcome (in the 
POISE III trial). The 
manufacturer provided 




(No metric of association 
reported)
No
(No quantified association 
reported)
No modelling approach 
was used (i.e. no 
assessment of the cost-
effectiveness of 
obeticholic acid took 
place)
According to ZIN there 
are limitations to the 
observational data 
including missing lab 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
study to support the 
choice for the biomarker. 
The FDA concluded that 
such cut-points were 
derived from a PBC 
population that was 
different from the one 
evaluated in trial 747-
301) 
values (potential bias) and 
the patient population did 
not match the trial 
population.
17. Ocriplasmin & vitreomacular traction: non-surgical resolution of focal vitreomacular adhesion
NICE No
There is limited evidence 
on the validity of non-
surgical resolution of 
vitreomacular adhesion as 






(No metric of association 
reported)
Yes
(No quantified association 
reported)
The manufacturer's model 
had 2 components: a 
short-term decision tree 




The primary outcome of 
vitreomacular adhesion 
resolution is a surrogate 
endpoint which has not 
been validated. EMA 
noted that its clinical 
relevance has not yet 
Yes 
(Unclear - There is 
evidence that it is related 
to improved visual 
acuity)
No
(No metric of association 
reported)
Yes
(No quantified association 
reported)
The model consisted of 6 
disease health states, based 
on vitreomacular traction, 
macular hole and vitrectomy 
The economic model 
consisted of a short term 
decision tree model, with 
outcomes at 28 days and 
6 months based on pooled 
data for ocriplasmin 
versus placebo injection 
from the two pivotal 
trials, and a Markov 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
been fully clarified 
although it was supported 
in the clinical studies 
programme by best 
corrected visual acuity 
data.
status, and within each 
disease state the patient could 
also be in one of 6 visual 
acuity health states (making 
36 possible visual acuity 
health states).
extrapolation with 3-
month cycles over a 
lifetime horizon, which 
was a maximum of 37.5 
years.
PBAC No
The PBAC considered it 
remained unclear how 
effective ocriplasmin is 
with respect to the patient 
relevant outcomes of 




(Unclear - The PBAC 
also noted that successful 
non-surgical VMT 
resolution at Day 28 did 
not appear to reliably 
predict avoidance of 
vitrectomy at 6 months. 
Overall,... any 
relationship between non-
surgical VMA resolution 
and extent of changes in 
visual acuity or visual 
disturbance or need for 
vitrectomy was not 
presented in the 
submission)
No
(No metric of association 
reported)
Yes 
(No quantified association 
reported)
The PBAC also noted that 
any relationship between 
another potential surrogate 
outcome, Full thickness 
macular hole closure, and 
extent of changes in visual 
acuity or visual disturbance 
or need for vitrectomy, was 
not explored in the 
submission.
Decision tree: to 6 months
Markov model 6 month 
cycles
31.5 years time horizon in 
the model base case 
versus 2 years in trial
The PBAC considered the 
evidence provided in the 
re-submission did not 
modify the Committee’s 
previous view, noting that 
data was now available 
for up to 24 months of 
follow-up.
CADTH Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
Yes
(No quantified association 
reported)
Decision tree + Markov 
model
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No




(No level of evidence 
reported)
No
(No metric of association 
reported)
No





18. Pertuzumab & HER2-positive breast cancer: pathological complete response/ invasive disease-free survival/progression-free survival
NICE Unclear
Both the FDA and EMA 
had concluded that it was 
'reasonably likely' that 
pathological complete 
response was associated 
with improved survival 
outcomes.
The committee agreed 




response could be viewed 
as a surrogate marker of 
long-term benefit.
Yes 
(Level I - CTNeoBC 
meta-analysis [27] 
identified a patient-level 
relationship between 
pathological complete 
response and survival, but 
could not validate 
pathological complete 
response as a valid 
surrogate for survival. 
Explore uncertainty in 
this area with a scenario 
analysis using the less 
robust survival data from 
NeoSphere, which 
improved the cost-
effectiveness results for 
Yes 
(CTNeoBC evaluated the 
prognostic value of 
pathological complete 
response. However, at 
trial-level, a treatment 
related improvement in 
pathological complete 
response that translated 
into a treatment-related 
improvement in survival 
outcomes was very weak 
(correlation coefficients 
of 0.03 and 0.24 for 




(No quantified association 
reported)
The company assumed that 
pathological complete 
response was a surrogate for 
survival in the model, 
because the event-free 
survival data from the trial 
were not robust enough to be 
used in the model. 
Surrogate section in 
NICE methods guidance 
referred to 
(Roche) - Although, 
significant uncertainty 
exists, much of this is as a 
result of the difference in 
the data accepted by the 
regulatory bodies versus 
that required by HTA 
bodies such as NICE.
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?




EMA did not consider the 
difference in tpCR rate 
between groups A and B 
in the NeoSphere study to 
be sufficiently large to 
translate into a significant 
difference with regard to 
DFS However, it is 
reasonably likely that 
neoadjuvant treatment 
with pertuzumab is 
associated with a benefit 
in terms of DFS/PFS and 
overall survival given 
(from the CLEOPATRA 
study).
Yes 
(Level I – CTNeoBC 
pooled analysis [27], 
funded by FDA, IPD with 
12 trials data, was 
undertaken to determine 
the relationship between 
pCR and long-term 
clinical benefits in 
neoadjuvant treatment of 
primary breast cancer. 
Whilst event-free and 
overall survival were 
improved in patients with 
tpCR compared to those 
without, the pooled 
analysis could not 
validate pCR as a 
surrogate endpoint for 
improved event-free and 
overall survival.
Yes 
(No metric of association 
reported)
Bayesian network meta-
analysis (NMA) that 
sought to provide 
evidence of the 
association between pCR 
after neoadjuvant therapy 
in HER2-positive breast 
cancer and improved 
long-term clinical 
outcomes. The model 
suggested that pCR was 
associated with improved 
event-free survival and 
overall survival versus 
non-pCR but the results 
were limited by 
heterogeneity in the 
NMA.
Yes 
In the base case, data 
informing the transition from 
EFS to loco-regional 
recurrence or metastatic 
disease were taken from the 
NeoSphere study. In order to 
model EFS rates over the 
longer term, tpCR rates from 
NeoSphere were combined 
with data from the CTNeoBC 
analysis. The tpCR rates from 
NeoSphere were used to 
weight the CTNeoBC curves 
on EFS associated with 
response/non response.
A Markov modelling 
structure was used which 
allowed for patients to be 
in states such as event-
free survival (EFS), 
locoregional recurrence 
(and remission there 
from), metastatic non-
progressed and metastatic 
progressed.
PBAC 2014 - 
2018
Yes
An improvement in DFS 
alone measured with a 
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
No mention of surrogacy 
in the document
The type of economic 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
hazard ratio with a lower 
limit 95% confidence 
interval between 0.65 and 
0.8 is considered a grade 
of clinical benefit that 
represents substantial 
improvement, based on 
ESMO-MCBS version 
1.0
evaluation presented was 
a cost-utility analysis. 
iDFS, Locoregional 
Recurrence, Remission, 
Distant Recurrence (1st 
line mBC), Distant 
Recurrence (2nd line 
mBC), Death 
A proposed risk share 
agreement was also 







Insufficient evidence to 
support the validity of 
pCR as a surrogate for 
long-term outcomes
Yes 
(Level I - A systematic 
review and meta-analysis 
that assessed the 
relationship between pCR 
and long-term outcomes 
in breast cancer was 
considered by pERC 
(Cortazar, 2014 [27]). 
(Level II - The 
NeoALTTO study [28] 
demonstrated that patients 
with a pCR had longer 
overall survival and 
Yes 
(No metric of association 
reported)
An association between 
pCR and event-free 
survival (EFS) and 
between pCR and overall 
survival was reported, at 
the individual level.
However, at the trial 
level, pERC noted that no 
association was 
demonstrated between 
increased frequency of 
Yes
(No quantified association 
reported)
The key clinical outcomes 
considered in the analysis 
were improvements in pCR 
that were extrapolated to 
estimate the extension of 
overall survival and 
improvements in health-
related quality of life
Two cost-utility analyses: 
one main analysis based 
on the NeoSphere study 
and a second analysis 
based on the 
TRYPHAENA study 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
event-free survival 
compared with patients 
without a pCR similar to 
the Cortazar meta-
analysis; however, the 
trial did not provide 
evidence that an 
improvement in the 
frequency of pCR is
associated with an 
improvement in event-
free survival or overall 
survival)
pCR and improvements in 
either EFS or overall 
survival. 
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No mention of surrogacy 
in the document
NIPN HTA Yes 
Cite The role of the 
pathological Complete 
Response as an endpoint 







(Level I - Cortazar et al. 
(CTNeoBC) 2014 [27])
No
(No metric of association 
reported)
No
(No quantified association 
reported)
Markov-model (6 health 
states: event-free survival; 
Locoregional Recurrence; 
Remission; Metastatic 
(1st line); Metastatic (2nd 
line); death)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?










and response rate are 
regarded as surrogate 
parameters of unclear 
validity in the present 
assessment
No
(As the pharmaceutical 
firm does not provide any 
documentation for the 
validation of the 
surrogates, the evaluation 
of these endpoints is not 
included) 
No
(No metric of association 
reported)
No









pirfenidone seemed to 
have a modest but 
measurable effect on 
slowing the decline in 
lung function, but that 
there was uncertainty in 
whether this benefit 
persisted over time 
Yes
(Level II - whilst some 
evidence on the validity 
of FVC as a surrogate for 
mortality and HRQoL is 
presented, a systematic 
search does not appear to 
have been conducted as 
other relevant papers 
presenting data on the 
correlation between FVC 
Yes 
(The CS cites one study 
showing that there is a 
moderate correlation 
between changes in 
percent predicted FVC 
and changes in a disease 
specific health-related 
quality of life (HRQoL) 
measure, (Spearman 
correlation coefficient of -
Yes 
(No quantified association 
reported)
The estimate of long-term 
mortality benefit with 
pirfenidone over a patient's 
lifetime by extrapolating 
from relatively short trials.
A micro-simulation approach 
The advantage of the 
model was that survival 
could be predicted by 
leveraging on primary 
and secondary
outcomes (FVC and 
6MWD) of the 
CAPACITY trials [30], 
which are known to be 
predictors of survival
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
because of the lack of 
data on pirfenidone’s 
effect on lung function 
beyond 72 weeks of 
treatment.
and HRQoL have not 
been summarised (du 
Bois et al. 2011 [29];)
0.32), but the correlation 
between absolute values 
for percent predicted FVC 
and HRQoL is weaker 
(Spearman correlation of 
-0.16))
whereby surrogate outcomes 
(FVC and 6MWD) are used 
to estimate the risk of IPF-
related mortality.  
SMC Unclear 
At present no validated 
surrogate endpoints and 
no threshold for clinically 
significant changes in 
measures of lung 
function, such as FVC. 
However, EMA 
concluded that percent-
predicted FVC is a well-
recognised measure of 
disease progression and 
prognosis in IPF 
Yes 
(Unclear - a recent 
editorial concluded that 
trends in FVC reliably 
predict mortality in IPF 
and is the best indicator 
of chronic disease 
progression, although not 
proven as a surrogate for 
mortality)
No
(No metric of association 
reported)
Yes 
(No quantified association 
reported)
Using the placebo data from 
the CAPACITY-1 and 2 
studies, a series of 
regressions were developed 
to estimate the relationship 
between these outcomes 
[IPF-related mortality, all 
cause hospitalisation and 
health related quality of life] 
and FVC and the 6MWD test 
outcomes as independent 
predictors
PBAC Unclear Yes 
(Level II - No significant 
difference for overall 
survival, as reported in 
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
No additional information 
available
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
the vital status-end of 
study analysis (this 
analysis was considered 
in an FDA review for 
pirfenidone to be most 
representative of the 
efficacy of a medicine in 
terms of disease 
modification/survival). 
CADTH/CDR Yes
FVC and the 6MWT are 
valid outcome measures 
[for mortality] in patients 
with mild to moderate 
IPF
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
Consideration of clinical 
effectiveness and cost 
effectiveness was based on 
pooled RCT analyses of 
mortality and life time 
extrapolation
The model used data from 
an observational trial to 
inform BSC mortality, 
and from a randomized 
controlled trial (RCT) 
with extension trial data 
to inform pirfenidone 
survival. 
The model‐predicted 
survival is similar to the 
RCT‐predicted survival 
(over the duration of the 
RCT), but fitted survival 
curves were used to 
estimate long‐term 
survival for both groups. 
HAS Yes No No No No economic model 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
The effectiveness of 
pirfenidone assessed on 
an intermediary outcome 
with a moderate amount 
of effect compared with 
placebo
(No level of evidence 
reported)
(No metric of association 
reported)
(No quantified association 
reported)
IQWIG/G-BA No
The validity of FVC as a 
surrogate for dyspnoea or 
overall survival was 
considered as not proven, 
based on the evidence 
provided by the applicant
Yes
(only for overall survival, 
although the individual 
studies presented were 
not considered of 
sufficient quality)
Yes
(the report explicitly 
sought information on the 
correlation between FVC 
and final outcomes, 
although this information 
was not provided by the 
applicant)
No
(No quantified association 
reported)
Details were not 
provided, as medicine 




FVC is an accepted 
surrogate-parameter for 





(No metric of association 
reported)
No 
(No quantified association 
reported)
ZIN states that based on 
the submitted data, it is 
not possible to verify the 
validity of the regression 
coefficients. Scatterplots 
showing a linear 
relationship between the 
surrogate outcomes and 
mortality are lacking
NIPN HTA Unclear No
(No level of evidence 
No
(No metric of association 
Unclear 
(No quantified association 
Cohort-partition model
The states used in the 
model are: PFS, 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
reported) reported) reported) Progressive state  
(defined as a 10% decline 
in predicted FVC, a 
decline in 6‑minute 
walking distance of 50 
metres or more), lung 
transplantation, and death
20. Ribociclib & hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer: progression free survival
NICE Unclear Yes
(Level II - Only 38.5% of 
the progression-free 
survival gain for 
palbociclib was translated 
into an overall survival 
gain (partial-OS 
surrogacy). The ERG 
suggested that partial-OS 
surrogacy is more 
plausible than full-OS 
surrogacy. But more 
recent data from the trial 
suggests that only 27.5% 
of progression-free 
survival gain translates 
into an overall survival 
gain)
No
(No metric of association 
reported)
No 
Overall survival is modelled 
indirectly and is a function of 
the time spent in each state.
The company's original base-
case analysis assumed that 
the progression-free survival 
gain for ribociclib seen in 
MONALEESA‑2 [31] 
translates into an equivalent 
overall survival gain (full-OS 
surrogacy). 
Patient-based state-
transition model with 
three health states 
(progression-free survival 
on first-line treatment, 
progression-free survival 
on second-line treatment, 
progression) and death. 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
SMC Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
State-transition model
OS was modelled as to 
reflect PFS gains 
identically
PBAC Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
July 2017: partitioned 
survival model wih a 10 
year time horizon
-model included both PFS 




PFS is an established and 
well agreed upon primary 





(No metric of association 
reported)
No 
(No quantified association 
reported)
Cohort-based partitioned 
survival model with 3 
health states. The PF state 
is further partitioned in 
two sub-states: PF with 
response (complete or 
partial response) and PF 
with stable disease. 
HAS Unclear No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 




The endpoint PFS is not 
patient-relevant in this 
Yes 
(Level I - The sources 
which are 
Yes 
(No metric of association 
reported)
Yes 





































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
operationalization per se unsystematically cited by 
the pharmaceutical firm 
are not suitable to prove 
the validity of PFS as a 
surrogate for symptoms, 
health-related quality of 
life or overall survival. In 
addition, the symptoms 
and health-related quality 
of life were measured 
directly in the 
MONALEESA-2 study. 
The pharmaceutical firm 
includes RCTs in its 
validation, in which 
adults with HR-positive, 
HER2-negative advanced 
or metastatic breast 
cancer were examined.)
A correlation analysis 
was performed with the 
calculation of the 
correlation coefficient 
according to Pearson. 
Since the result does not 
allow any conclusive 
statement on the validity 
of the surrogate, a 
surrogate threshold effect 
(STE) was additionally 
calculated on the basis of 
the regression model 
mentioned above. 
The pharmaceutical firm 
finds that the difference in 
the median of the PFS 
endpoint in the 
MONALEESA-2 [31] 
treatment arms is higher than 
the determined STE and thus 
a statement on the effect of 
treatment on overall survival 
can be derived from the 
effect on PFS.
ZIN Yes
Although PFS is a 
surrogate outcome 
measure, it was deemed 
unlikely that with 
corresponding effects on 
PFS (between ribociclib 
and palbociclib) the 
No
(No level of evidence 
reported)
No
(No metric of association 
reported)
No 
(No quantified association 
reported)
No modelling approach 
was used (i.e. no 
assessment of the cost-
effectiveness of ribociclib 
took place)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
effects on hard outcome 
measures would differ to 
a relevant extent between 
the two medicines.
NIPN HTA Unclear No No
(No metric of association 
reported)
No 
(No quantified association 
reported)
Markov-model (3 health 
states: progression-free, 
progressed, death) cohort-
based partitioned survival 
model
21. Tolvaptan & autosomal dominant polycystic kidney disease: total kidney volume/ Estimated glomerular filtration rate
NICE Yes
In its report, the ERG 
considered that TKV as a 
surrogate end point for 
annual eGFR decline had 
limited value, but that it 
was a good measure of 
extent of disease because 





(No metric of association 
reported)
Yes 
(No quantified association 
reported)
The underlying risk of 
disease progression was 
modelled using regression 
equations to predict annual 
change in TKV and 
glomerular filtration rate 
(eGFR).
Annual change in TKV 
was used as an 
intermediate step to 
model change in eGFR, 
which was the primary 
outcome of the model 
(eGFR was dependent on 
TKV in the previous 
cycle).
In the revised model, 
annual change in renal 
function and % TKV 
change estimated using 
regression equations 
instead of data observed 
for the first 3 years over 
the trial period.
SMC Yes Yes Yes No
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
Increase in TKV 
correlates to growth in 
cyst volume and was 
considered to be an 
appropriate surrogate for 
disease progression by 
the EMA
(Level II – Kistler et al. 
2009 [32])
(No metric of association 
reported)
(No quantified association 
reported)
PBAC Unclear
The PBAC has not 
previously considered this 
outcome in this 
therapeutic area or 
accepted the relevance of 
TKV as a surrogate 
outcome for kidney 
disease progression
Yes
March 2018: PBAC 
accepted eGFR as a 
reasonable surrogate for 
end-stage kidney disease 
(ESKD) “albeit not 
validated in this setting”
Yes
(Level II - Although 
baseline TKV is 
correlated with long-term 
renal function decline 
(i.e. future decline in 
renal function is predicted 
by baseline TKV), the 
ESC was concerned that 
there is no validated 
correlation between 
growth in TKV and rate 
of decline of eGFR, or 
time to ESKD, and that 
there is even some 
evidence to suggest 
dissociation between 
these outcomes (Ong et 
al. 2015 [33]) 
Yes
(No metric of association 
reported)
As explained in a review 
of the clinical 
management of ASPKD, 
Ong et al. (2015) [33], 
“[a]lthough most 
biomarkers correlated 
with eGFR, whether these 
markers can predict 
disease progression more 





(No quantified association 
reported)
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
CADTH Unclear
The relationship between 
TKV and clinically 
important end points 
(such as delaying or 
preventing ESRD or need 
for hemodialysis) remains 
to be elucidated. It is 
considered a surrogate 
outcome for cyst 
development in ADPKD.
Yes 
(Level II - The 
Consortium for 
Radiologic Imaging 
Studies of Polycystic 
Kidney Disease (CRISP) 
observational study found 
that height-adjusted TKV 
(htTKV) was correlated 
inversely with glomerular 
filtration rate (GFR) and 
had potential to predict 
development of Stage 3 
CKD. No minimal 
clinically important 
difference (MCID) for 
change in TKV was 
identified (Chapman et al. 
2012 [34])
Yes 
The association of TKV 
with kidney function was 
assessed in an eight-year 
observational study 
(CRISP) and the pivotal 
study (TEMPO 3:4 [35]).
Based on the calculation 
of Pearson correlation 
coefficients and 
corresponding P values, a 
statistically significant 
negative correlation 
between htTKV and GFR, 
which increased from a 
weak correlation at 
baseline (r = –0.22, P = 
0.02) to a moderate 
correlation at year 8 (r = –
0.65, P = 0.001), was 
found. Therefore, htTKV 
is considered a good 
biomarker for kidney 
disease progression, 
although it is not perfect.
Yes
For each 100 mL/m change 
in htTKV, a 48% (95% CI, 
29% to 70%) increase in odds 
of progression to Stage 3 
CKD was estimated. Similar 
ORs and levels of 
significance were seen with 
estimated glomerular 
filtration rate (eGFR) 
determinations. In area under 
receiver operator 
characteristic (AUROC) 
analysis, it was reported that 
baseline htTKV of 600 mL/m 
most accurately defined the 
risk of developing Stage 3 
CKD within eight years with 
an AUROC of 0.84 (95% CI, 
0.79 to 0.90).
TKV is gaining clinical 
and regulatory acceptance 
as a valid surrogate 
marker to assess 
outcomes of medicine 
interventions for 
ADPKD. MRI is 
considered the gold 
standard method for 
measuring TKV, though it 
is not easily accessible or 
feasible in the routine 
monitoring of patients.
HAS Yes Yes No No
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?




(Level II - This 
intermediate criterion was 
chosen following the 
CRISP study set up by 
the NIH [36])
(No metric of association 
reported)
(No quantified association 
reported)
ZIN Yes
TKV as a surrogate 
outcome measure for 
ADPKD is supported by 
Kidney Disease: 
Improving Global 
Outcomes (KDIGO), was 
accepted by the EMA in 
the European product 
assessment report 
(EPAR)
TKV is seen as a 
predictor of ADPKD 
progression and change in 
TKV can predict change 
in renal function (eGFR), 
and thus also change of 
disease stage (CKD 
stage) and the 
development of ESRD
Yes 
(Level II - The literature 
supports total kidney 
volume as a marker for 
progression of ADPKD 
and TKV was also 
associated with a 
decrease in renal function 
in the TEMPO 3: 4 study 
[35]) 
Yes 
(TKV is correlated in the 
literature with the 
glomerular filtration rate 
(GFR) over a period of 3 
to 8 years. Adjusted total 
kidney volume of 600 ml 
or higher predicts the risk 
of CKD stage 3 over a 
period of 8 years with an 
area under the curve 
(AUC) of 0.8420.
Yes
In the model, the progression 
of renal insufficiency is 
determined based on the 
estimated glomerular 
filtration rate (eGFR) based 
on serum creatinine (using 
the CKD-EPI formula).
Micro-simulation - 
Patients are individually 
simulated through the 
model in annual cycles.
The model distinguishes 
two separate modules: an 
ADPKD module and a 
module ESRD. 
22. Integrated sensor-augmented pump therapy & type 1 diabetes: HbA1c/ time spent in normo-hypo-hyperglycaemia/ hypoglycaemic events
NICE Yes Yes No Yes IMS CORE Diabetes 
































































Agency Surrogate accepted? Level of evidence 
considered? 
(If so, what’s the stated 
level)
Strength of association 
considered?
(If so, what’s the stated 
level)
Quantification of association 
considered?
(If so, what’s the stated level) 
Comment 
HbA1c was an 
established and accepted 
surrogate outcome 
measure that has been 
shown to be associated 
with clinical outcomes
(Level I - The Committee 
considered the validity of 
HbA1c as a primary 
endpoint in the studies 
included in the meta-
analyses) 
(No metric of association 
reported)
(No quantified association 
reported)
Using HbA1c in the analyses 
was reasonable and provided 
a link to long-term outcomes.
Model was used, with a 
time horizon of 60 years 
and included a population 
with an average age of 






(No metric of association 
reported)
No 
(No quantified association 
reported)
23. Geko device & venous thromboembolism: blood flow
NICE Yes
The Committee accepted 
that the available data on 
measurements of blood 
flow provide some 
support for the claim that 
the device reduces the 
risk of venous 
thromboembolism
Yes 
(Expert opinion - The 
Committee heard a range 
of expert opinions. 
However, further research 
is needed to confirm that 
the Geko device reduces 
the incidence of venous 
thromboembolism in 
clinical practice, and to 
demonstrate conclusively 
the size of the risk 
reduction associated with 
its use)
No
(No metric of association 
reported)
No
(No quantified association 
reported)
No evidence was available 
for the reduction in RR of 
DVT associated with the use 
of the geko device. The 
sponsor's assumption of RR 
of 0.39 was based on the 
incidence of subclinical DVT 
after the use of 
neuromuscular 
electrostimulation as reported 
in Browse & Negus (1970)
Decision-tree model
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Supplementary Table 2 Inter-agency agreement on the acceptability of surrogate endpoint
NICE SMC PBAC HAS CADTH IQWiG/G-BA ZIN NIPN HTA
NICE - 0.53* 0.00 0.03 0.05 0.00 0.18 -0.03
SMC - 0.10 0.37 -0.07 0.00 0.05 0.23
PBAC - 0.30 -0.09 0.00 -0.30 0.71*
HAS - 0.26 0.00 0.37 0.23
CADTH - 0.00 -0.24 -0.12




Supplementary Table 3 Inter-agency agreement on the final r commendation given
NICE SMC PBAC HAS CADTH IQWiG/G-BA ZIN
NICE - 0.14 -0.10 0.14 -0.14 0.00 0.00
SMC - -0.07 0.06 0.03 0.35* -
0.20
PBAC - 0.10 0.00 0.00 1.00
HAS - 0.25 0.70* 0.38








































































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
1. Alirocumab






























































Acceptability of SE YES YES YES YES YES NO YES YES



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Date / decision 06/2016,  07/2016,  11/2017,  07/2016,  04/2017,  02/2018,  02/2016,  02/2016




































Included in a 
reimbursemen
t cluster with 
evolocumab 
(Bijlage 1A).







































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
demonstrated
2. Axitinib















Surrogate and final 
outcome
progression-free survival (PFS) for overall survival (OS) PFS for OS



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Acceptability of SE YES Unclear NO YES Unclear Unclear Unclear
Date / decision
02/2015,  07/2013,  11/2013, 
11/2014, 
07/2012,  01/2013,  09/2017,  N.a. 01/2013
Comments related to the 
decision





























Comparators rituximab (R- rituximab (R- vincristine 



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
CHOP) CHOP) (ONCOVIN)
Surrogate and final 
outcome
PFS for OS PFS for OS
Acceptability of SE YES YES Unclear
Date / decision 12/2015,  08/2015,  N.a. N.a. 01/2016,  N.a. N.a. N.a.
Comments related to the 
decision
4. Bortezomib
























































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
dexamethason
e













PFS for OS overall 
survival used 
instead
Acceptability of SE YES YES NO Unclear NO
Date / decision 04/2014,  12/2013,  03/2012,  02/2013,  01/2014,  N.a. N.a. N.a.



































































































SE and final outcome
Date / decision
Comments related to the 
decision








































imatinib Imatinib imatinib, 
nilotinib and 
dasatinib
Surrogate and final 
outcome
MCyR for OS No SO; OS 
data used







Acceptability of SE YES Unclear YES Unclear NO Unclear



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Date / decision 08/2016,  01/2015,  N.a. 04/2015,  02/2014,  05/2018,  N.a. 12/2015
Comments related to the 
decision
Restricted to 
2nd line with 





































with high risk 














Comparators chemotherapy chemotherapy 
+/- 







































































SE and final outcome
Date / decision
Comments related to the 
decision














Surrogate and final 
outcome
PFS for OS OS data was 
used in the 
end
PFS for OS OS data was 
used in the 
end
PFS and EFS 
for OS
Acceptability of SE YES NO YES NO NO
Date / decision







































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Comments related to the 
decision
Approved 












































































































SE and final outcome
Date / decision
Comments related to the 
decision





Surrogate and final 
outcome












response  for 
OS
Acceptability of SE YES Unclear Unclear Unclear Unclear NO Unclear
Date / decision 10/2016,  08/2016,  03/2016,  06/2016,  12/2016,  12/2015,  07/2016








due to no 
submission 
by 

















given by the 
company







































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
manufacturer OS data OS data
8. Dasatinib
Target population
newly diagnosed Philadelphia chromosome 
positive (Ph+) chronic myelogenous leukaemia 














to CCyR for 
OS
Acceptability of SE YES YES NO
Date / decision
12/2016,  08/2016,  07/2011, 
08/2016, 



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN









































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
















Acceptability of SE YES Unclear Unclear Unclear YES
Date / decision
12/2016,  08/2016,  03/2007,  03/2007, 
10/2018, 
03/2007, 
































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN












patients with advanced 
hormone-dependent prostate 
cancer




Surrogate and final 
outcome


















Acceptability of SE NO Unclear YES Unclear Unclear



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Date / decision



























































Comparators placebo cinacalcet cinacalcet cinacalcet



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
cinacalcet

















Acceptability of SE Unclear Unclear Unclear Unclear Unclear
Date / decision 06/2016,  08/2017,  04/2017,  08/2017,  03/2017, 














































































































SE and final outcome
Date / decision
Comments related to the 
decision
































, and adults 
and children 






























































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
LDL 
apheresis
Surrogate and final 
outcome
LDL-C levels for CV events
Acceptability of SE YES YES Unclear NO Unclear Unclear YES Unclear
Date / decision
06/2016,  01/2017,  03/2016, 
11/2017, 
07/2018, 
11/2017,  12/2015, 
09/2018, 
06/2018,  12/2015,  11/2015

















































impact on the 







































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
proposed health care 
budget.
13. Imatinib
Target population gastrointestinal stromal tumours
Comparators Best supportive care
Surrogate and final 
outcome
recurrence-free survival as a surrogate outcome 
for overall survival
Acceptability of SE Unclear Unclear Unclear
Date / decision
















































































SE and final outcome
Date / decision
Comments related to the 
decision












































- sofosbuvir + 
daclatasvir
- sofosbuvir + 
simeprevir












































































SE and final outcome
Date / decision
Comments related to the 
decision


































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
care
Surrogate and final 
outcome
SVR at 12 weeks post 
treatment (SVR12) for 
treatment efficacy
SVR at 12 weeks post treatment (SVR12) for treatment efficacy
Acceptability of SE YES YES YES YES NO YES Unclear
Date / decision





05/2015,  02/2015,  05/2015,  05/2015, 





























































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN






Surrogate and final 
outcome
serum uric 











Acceptability of SE YES Unclear
Date / decision 02/2018,  04/2018, 














































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
16. Obeticholic acid
Target population primary biliary cholangitis primary biliary cholangitis
Comparators placebo placebo
Surrogate and final 
outcome
alkaline phosphatase (ALP) 
and bilirubin at 12-months for 
overall survival
alkaline phosphatase (ALP) and bilirubin at 12-months for 
overall survival
Acceptability of SE YES YES YES NO NO NO
Date / decision 04/2017,  05/2017,  07/2017,  09/2017,  04/2014,  06/2018, 
Comments related to the 
decision
Restricted 
within a PAS, 




























Target population vitreomacular traction



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Comparators



























































Acceptability of SE NO NO NO Unclear Unclear Unclear
Date / decision
10/2013,  07/2014,  11/2014, 
03/2016, 
12/2014,  12/2013, 
12/2017, 
07/2013, 



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN





























Radiotherapy trastuzumab + 
docetaxel






































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Acceptability of SE Unclear Unclear YES NO Unclear NO YES
Date / decision





07/2016,  06/2013,  03/2016,










































Best supportive care + placebo



































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
care care care care care
Surrogate and final 
outcome
FVC FVC FVC FVC FVC FVC FVC FVC
Acceptability of SE Unclear Unclear Unclear YES YES NO YES Unclear
Date / decision





02/2015,  02/2015,  09/2013,  06/2015









































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
20. Ribociclib
Target population Previously untreated postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer
Comparators Aromataze inhibitor (letrozole) +/- palbociclib
Surrogate and final 
outcome
PFS for OS
Acceptability of SE Unclear Unclear Unclear YES Unclear NO YES Unclear
Date / decision
12/2017,  02/2018,  07/2017, 
11/2017, 
03/2018, 
04/2018,  01/2018,  12/2017,  10/2017,  01/2018

























on to amend 
current price 
to improve 







































































SE and final outcome
Date / decision
Comments related to the 
decision

















Placebo / best supportive care best 
supportive 
care
Surrogate and final 
outcome







































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Acceptability of SE YES YES YES Unclear YES YES
Date / decision
10/2015,  12/2015,  03/2017, 
03/2018, 
07/2018, 
02/2016,  12/2015,  12/2015, 











mainly due to 
limited 
evidence on 














22. Integrated insulin pump systems (MiniMed Paradigm Veo, DEXCOM G4 PLATINUM)
Target population Diabetes type Diabetes type 



































































SE and final outcome
Date / decision
Comments related to the 
decision










































































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
PLATINUM with a RSA
23. The geko device
Target population
people who 
have a high 


















































































SE and final outcome
Date / decision
Comments related to the 
decision
NICE HIS/SMC PBAC/MSAC CADTH HAS IQWiG/G-BA ZIN NIPN
Acceptability of SE YES
Date / decision 06/2014, 
Comments related to the 
decision
Note:  = approved for reimbursement;  = restricted reimbursement (either restricted prescription or subject to a price change);  = rejected.
SO = surrogate outcomes; N.a. = not evaluated (no document was identified); ICER = incremental cost-effectiveness ratio; OS = overall 
survival; PFS = progression-free survival; MCyR = major cytogenetic response; PAS = patient access scheme; RSA = risk sharing agreement); 
TOT = time on treatment 
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ABSTRACT
Background: Health technologies are increasingly approved on the basis of sSurrogate 
endpoints, i.e., intermediate endpoints intended to predict for the patient-centered outcomes, 
are increasingly common. However, little is known about how surrogate evidence is handled 
in the context of health technology assessment (HTA). 
Objectives: (i) to map methodologies for the validation of surrogate endpoints and (ii) to 
determine their impact on acceptability of surrogates and coverage decisions made by HTA 
agencies.
Methods: We sought HTA reports where evaluation relied on a surrogate were sought from 
eight HTA agencies. We extracted dData was extracted on the methods applied for surrogate 
validation (i.e., level of evidence, strength of association, quantification of the expected effect 
on patient-centered endpoint). We assessed determined the level of agreement between 
agencies and fitted mixed-effects logistic regression models to test the impact of validation 
approaches on the agency’s acceptability of the surrogat  endpoint by an agency and their 
coverage recommendation.
Results: Of the 124 included reports, 61 (49%) discussed the level of evidence to support the 
relationship between the surrogate and the patient-centered endpoint, 27 (22%) reported a 
correlation coefficient/association measure, and 40 (32%) quantified the expected effect on 
the patient-centered outcome. Overall, the surrogate endpoint was deemed acceptable in 49 
(40%) reports (k-coefficient 0.10, p=0.004). Any cConsideration of the level of evidence was 
associated with accepting ability of the validity of the surrogate endpoint as validby HTA 
agencies (odds ratio (OR) 4.60, 95% confidence interval (CI): CI 1.60 to 13.18, p=0.005). 
However, we did not find strong evidence of the an association between acceptingance as 
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valid the surrogate endpoint and agency coverage recommendation (OR 0.71, CI: 0.23 to 
2.20. p=0.55). 
Conclusions: Handling of surrogate endpoint evidence in evaluation reports varied greatly 
across HTA agencies, with inconsistent consideration of the level of evidence and statistical 
validation. Our findings call for careful reconsideration of the issue of surrogacy and the need 
for harmonization of practices across international HTA agencies. 
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Background
In recent years, regulatory agencies, including the European Medicines Agency (EMA) and 
the Food and Drug Administration (FDA) in the United States, have increasingly approved 
drugs and biologics on the basis of surrogate endpoints (1). A surrogate endpoint is defined 
as a biomarker or physiological measure, laboratory test result, imaging result, or another 
replacement end point that is thought to capture the causal pathway through which the 
disease process affects the patient-centered outcomes (2).
When used as primary outcomes, surrogate endpoints enable clinical trials of smaller sample 
size, shorter duration, and lower cost than trials with a patient-centered primary endpoint (3). 
The uptake of surrogate endpoints in pivotal trials is typically associated with expedited drug 
review and accelerated approval programs resulting in grant market authorization on the basis 
ofbased on less rigorous evidence, i.e., fewer and smaller studies, without an appropriate 
comparator, or single-arm studies (4). However, once licensed, patient access to these 
products typically depends on assessment by an health technology assessment (HTA) agency 
that informs  face the a country’s or region’s payers’ or coverage of reimbursement decision. 
and reimbursement committees’ scrutiny which varies widely between jurisdictions, and 
often even within the same region (5). Whilst regulatory bodies agencies are primarily 
concerned with the efficacy-safety of health technologies, HTA health technology assessment 
(HTA) agencies seek to assess are their the long-term comparative effectiveness and 
economic consequences of health technologies, alongside other considerations such as equity, 
severity of disease, or unmet need. Recent research has shown that HTA the  methodologicals 
guidelines of HTA agencies often take a conservative approach to the use of surrogate 
endpoints to support their coverage recommendations, i.e,for example by (1a) expressing a 
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preference for patient-relevant outcomes (such as mortality); (b2) recommending that 
surrogate endpoints should only be used in situations where patient-relevant outcomes are not 
available or their evidence is limited, and or (c3) limiting use of surrogate outcomes should 
be limited to validated measures (6, 7). 
Four previous studies have investigated the impact of surrogate endpoints on consideration in 
HTA decisions. Two studies focused on cancer drugs (16, 17) , and the other two considered 
the range of technology appraisals undertaken by either National Institute of Health and Care 
Excellence (NICE) in United Kingdom or the Canadian Common Drug Review (18, 19). 
However, none of these previous studies did not assess HTA agencies examined the approach 
to validation of the surrogate endpoints or how this related to their coverage 
recommendation. 
The objectives of this study were: (i) to map the range of methodological approaches for the 
validation of surrogate endpoints applied adopted in HTA reports across a an international 
sample of international HTA agencies and (ii) to assess how the consideration of the validity 
of the surrogate endpoints considered influences the coverage or reimbursement decisions 
made by these agencies.
Methods
Selection of HTA reports
We applied a two-step approach to the selection and inclusion of HTA reports in this study. 
First, we sought to identify health technologies and related HTA reports that involved the use 
of surrogate endpoints. We used the The surrogate endpoint definition of the US National 
Institutes of Health was used i.e., a biomarker (or intermediate endpoint) intended to 
substitute for a clinical endpoint (20). We screened the guidance published by NICE between 
May 2013 and June 2018. All technology appraisal guidance, medical technologies guidance, 
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and diagnostics guidance reports published in this timeframe were screened by one of the 
research team (BG) for inclusion on the basis that they included discussion of a surrogate 
endpoint or surrogacy issue. 
Second, based on a once we had identified  a selected list of NICE evaluations (and HTA 
reports) for inclusion, we then identified HTA evaluation reports for the same health 
technology and clinical indication from a further sample of selected six HTA agencies. These 
agencies included; , i.e., Health Improvement Scotland (HIS)/ Scottish Medicines 
Consortium (SMC) in Scotland, Haute Autorité de Santé (HAS) in France, Pharmaceutical 
Benefits Advisory Committee (PBAC) and Medical Services Advisory Committee (MSAC) 
in Australia, Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, 
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)/ Gemeinsame 
Bundesausschuss (G-BA) in Germany, Zorginstituut Nederland (ZiN) in the Netherlands, and 
Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (NIPN) in Hungary. These 
agencies span different geographical areas, include some of the most prominent HTA 
organizations worldwide, and are known to follow methodological guidelines that include 
consideration of surrogate endpoints, with different levels of detail (7). Between August and 
September 2018, we sought all relevant reports from these agencies, irrespective of language 
and publication date.
Framework for assessment and validation of surrogate endpoints 
The validation of surrogate endpoints is a complex subject. In the biostatistics literature 
several approaches have been discussed that , from a regulatory perspective, would be 
suitable to identify when is a biomarkera biomarker is ‘likely to predict’ a patient-centered 
endpoint of interest (8). Most common methods are framed within the causal inference and 
meta-analytic paradigms (9, 10). The two-stage meta-analytic approach developed by Buyse 
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et al. requires demonstration of strong correlation between the surrogate and definitive 
endpoints (‘individual-level surrogacy’) as well as correlation of treatment effects on both 
endpoints (‘trial-level surrogacy’). Meta-analysis of individual patient data (IPD) remains the 
optimal approach because it enables the standardization of methods across IPD sets and 
robust analysis at both the patient and trial levels. However, because IPD meta-analyses are 
time and resource intensive, meta-analyses of outcome correlation or trial-level associations 
using aggregate data are more often reported.  In this setting, mBayesian multivariate meta-
analytic methods in the Bayesian framework of estimation are increasingly used, as they take 
into account the correlation between the treatment effects on the surrogate and final patient-
centered outcomes as wellin addition to as the uncertainty related to all parameters 
describingin  the surrogate relationship (11).
A recent overview of HTA guidelines, identified only five HTA agencies provideing detailed 
advice on the statistical methods that should to be used for the validation of surrogate 
endpoints (7). These guidelines notewithin a common recognition across these guidelines of 
the current lack of methodological consensus on the around necessary minimum criteria to 
establish the validity of surrogates (7). Numerical values discussed as thresholds for 
acceptable surrogacy include are a coefficient of determination R² ≥ 0.6 or 0.7 (12, 13), or a 
coefficient of correlation R ≥ 0.85 (14). 
In 2017, Ciani et al proposed a methodological framework for the incorporation and reporting 
of the use of surrogate endpoints in HTA (15). A three-step approach was recommended: (i) 
to establish the level of evidence available (i.e., whether the relationship between the putative 
surrogate endpoint and patient-centered endpoint of interest is supported by clinical 
plausibility, observational data or meta-analyses of multiple randomised controlled trials); (ii) 
to assess the strength of the association between the surrogate and patient-centered outcomes: 
observational association or treatment effect assessment (e.g., correlation coefficient at the 
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individual and at the trial level); (iii) to quantify the expected effect on the patient-centered 
outcome given the observed effect on the surrogate endpoint. Table 1 elaborates this 3-stage 
methodological framework, illustrated with examples of good practice. 
Table 1 Methods for the validation of surrogate endpoints – 3 stage framework
Data extraction from reports
We developed aA structured extraction form for included HTA reports was developed based 
on the above framework, previous studies (21), and the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist (22). We considered the following 
categories of information: general characteristics of the evaluation/report, characteristics of 
the health technology, and orphan status designation. Orphan designation is attributed to 
medicines that are intended to treatment, prevention or diagnosis of a rare disease (usually no 
more than 5 in 10,000 in the relevant jurisdiction) that is life-threatening or chronically 
debilitating;; that is are unlikely to generate sufficient returns to justify the investment needed 
for the medicines’ development, and such that the medicinethat provides a significant benefit 
in relation to the efficacy or safety of the treatment, prevention or diagnosis of the same 
condition (23, 24, 25).
We analysed characteristics of the included surrogate endpoint (i.e., source of evidence, 
justification for use, methods for validation, how surrogate endpoint was incorporated in 
economic modelling (if undertaken), and other considerations), how uncertainty was dealt 
with in relation to consideration of surrogate endpoint (including restricted coverage or price 
discounts), and final coverage/reimbursement policy recommendation given. Following the 
three-step validation framework described above (15), we assessed: specifically (1) the level 
of evidence – if any – available to support the surrogate-to-final outcome relationship (e.g. an 
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individual patient data meta-analysis of RCTs would represent the highest level of evidence); 
(2) whether the report discussed the association between surrogate and final outcome with a 
related metric (e.g. spearman’s ρ) given; and (3) whether the report discussed quantification 
of the expected treatment effect on the patient-centered endpoint based on the observed effect 
on the surrogate endpoint, either from previous evidence or based on the decision model 
developed in the report (Table 1). In addition, we assessed collected information on the level 
of acceptability of the surrogate endpoint. as judged in each single report based on the 
evaluation performed. For example,  (e.g., “increase in total kidney volume correlates to 
growth in cyst volume and was considered to be an appropriate surrogate for disease 
progression” would be a statement that indicates acceptability of total kidney volume as a 
surrogate by the appraisal committee). Finally, we investigated how the surrogate endpoint -
related information was used in the development of the cost-effectiveness model and the 
reimbursement/coverage recommendation made. In this respect, Wwe recorded if  eventual 
finance-based (e.g., ‘Patient Access Schemes’ in the United Kingdom intended to provide the 
National Health Service with access to the technology based on at a confidential discounts 
from list price) or performance-based risk-sharing arrangements (e.g., plans to track the 
performance of the product over a specified period of time so to inform the amount or level 
of reimbursement based on the health outcomes achieved) were agreed with the manufacturer 
(26). 
The data extraction form was piloted on three HTA reports (by OC, BG, RST). Following 
this pilot, information was extracted from each HTA report by one of the authors. Non-
English reports were data extracted by co-authors who were native or proficient speakers and 
translated into English. A random sample of the reports (n=36) was checked for accuracy of 
data extraction by another member of the team (either OC, BG or RT). 
Data analysis and synthesis
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We used tTables and descriptive statistics were used to summarise extracted data and enable 
comparison of information across agencies (for a given health technology) and within 
agencies (across HTA reports). Two key areas of results presentation are: (i1) the 
methodological handling of surrogate endpoints in HTA reports and how this influences the 
acceptability of surrogate endpoints, and ; (ii2) how surrogate endpoints validity influences 
the final reimbursement/coverage recommendation made by HTA agencies. In case of 
multiple evaluations made by an agency for the same technology, we considered the latest 
evaluation. Given that clinical evidence often accumulates after marketing authorization, we 
considered this to be a conservative approach, i.e., looking at the highest evidence base for 
surrogate validation.
We determined tThe level of agreement between agencies in terms of acceptability of 
surrogate endpoint and final recommendations made was determined using a generalization 
of the kappa coefficient for binary observations and multiple observers. We interpreted 
Kappa values were interpreted as follows: values ≤ 0 as indicating no agreement and 0.01–
0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as substantial, 
and 0.81–1.00 as almost perfect agreement (27).
We collapsed cCategorical variables were collapsed into binary responses (acceptable 
surrogate vs no/unclear; approved technology vs rejected/restricted), and we fitted 
univariable and multivariable mixed-effects logistic regression models were fitted to test: (1 ) 
the impact of level of evidence, reporting a metric of association, quantifying the expected 
effect on the patient-centered outcome, and orphan status, on the HTA agency’s acceptability 
of the surrogate endpoint; and (2) the impact of the acceptability of the surrogate endpoint 
(and previous variables) on the final coverage recommendations given by the HTA agency. 
We applied the sStandard two-tailed p<0.05 threshold for the interpretation of statistical 
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significance of regression coefficients was applied. We conducted aAll statistical analyses 
were conducted in Stata/SE 16.1.
Results
Description of health technologies under assessment and included reports
We screened aA total of 291 HTA reports from NICE were screened, of which 23 (8%) were 
included in the analysis. Among the 23 technologies assessed, 21 (91%) were 
pharmaceuticals and two (9%) were medical devices. Twelve (52%) technologies were used 
for an oncology indication, three (13%) for a cardiovascular indication, two (9%) for either 
endocrinology or nephrology indication, and the remainder spread across a variety of 
conditions (i.e., chronic hepatitis C, biliary cholangitis, vitreomacular traction, pulmonary 
fibrosis). A summary of the technologies included is available in Table 2.
Table 2 Characteristics of health technologies and related HTA evaluation
The most frequently considered surrogate endpoint was progression-free survival and was 
used in the evaluation of seven (30%) technologies (Axitinib, two indications of Bortezomib, 
Brentuximab, Cobimetinib, Pertuzumab, Ribociclib), all intended for oncology indications. 
Major/complete cytogenetic response was used in four (17%) oncologic evaluations 
(Bosutinib, Dasatinib first and second line, Pertuzumab). Changes in low-density lipoprotein 
cholesterol levels were used in two (9%) technologies intended for dyslipidaemia 
(Alirocumab, Evolocumab). Other surrogate endpoints were either biomarkers (parathyroid 
hormone, testosterone level, prostate specific antigen, alkaline phosphatase, bilirubin, 
glycated haemoglobin, sustained virologic response), functional measurements (forced vital 
capacity, venous blood flow, change in total kidney volume), or measure of clinical response 
(e.g., proportion of patients with non-surgical resolution of focal vitreomacular traction). 
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We identified a total of 124 reports across all eight HTA agencies matching these NICE 
appraisals (Figure 1). These reports included a total of 341 archived documents (including the 
reports, associated recommendations, appendices, and responses to consultation) that were 
obtained and screened for data extraction (see Supplementary Material). Four technologies 
(Alirocumab, Evolocumab, Pirfenidone, Ribociclib) were evaluated across all eight agencies. 
One technology (’the geko device, FirstKind Ltd) was only evaluated by NICE. The median 
number of evaluations per technology was five.
Figure 1 Flow diagram of HTA report selection 
How validation of surrogate endpoints is empirically addressed in HTA reports
To investigate how the validation of putative surrogate endpoints was addressed in practice, 
each of the 124 unique reports was considered as a separate observation (Table 3). 
Table 3 Summary of characteristics of HTA reports
The level of evidence to establish the validity of the surrogate was clearly assessed in 61 
(49%) evaluations and not assessed in 57 (46%). In the other 6 reports this information was 
unclear (5%). Only 27 reports (22%) reported a measure of strength of association between 
the putative surrogate endpoint and the patient-relevant endpoint of interest and in the 
majority of the evaluations (97, 78%) there was no correlation metric reported. Forty (32%) 
evaluations quantified the predicted effect of the surrogate endpoint on the patient-centered 
outcome; the majority of reports did not (72, 58%) or failed not provide enough information 
(12, 10%) for us to judge whether this was actually done. The surrogate endpoints were 
overall deemed ‘acceptable’ in 49 reports (40%), ‘unacceptable’ in 23 (18%), with no clear 
statement on acceptability provided in the remaining 52 (42%) evaluations (Supplementary 
Table 1). 
































































                                                                             
15
Variation between agencies 
The level of depth and scrutiny applied by different agencies in relation to the validation of 
surrogate endpoints varied (Figure 2). NICE was the agency most likely to report on the level 
of evidence (22/23), strength of association (7/23) and quantification of effect (17/23) related 
to the validation of a putative surrogate endpoint. In contrast, HAS and NIPN were the 
agencies with the least level of information reported in terms of validation. 
Figure 2 Steps of the validation of surrogate endpoints performed by HTA agencies
IQWiG appeared to apply a particularly strict approach with respect to the acceptability of 
surrogate endpoints, with no surrogate outcome explicitly deemed valid. Pairwise kappa 
coefficients revealed moderate to substantial (>0.40) agreement on the acceptability of the 
surrogate endpoint between NICE and SMC, and between PBAC and NIPN HTA. Overall, 
there was very low level of agreement across the eight agencies was 0.10 (p = 0.04) 
(Supplementary Table 2). 
Variation between health technologies 
High consistency in the acceptability was seen for cholesterol level used in the assessment of 
Alirocumab in hypercholesterolaemia (only IQWiG did not accept the validity of this 
putative surrogate endpoint (28)) (Supplementary Figure 1). Total kidney volume used in the 
assessment of Tolvaptan in autosomal dominant polycystic kidney disease was accepted in 5 
out 6 assessments (CADTH stated that the relationship between total kidney volume and 
clinically important end points ‘remains to be elucidated’ (29)). For other health 
technologies, conclusions about the validity of the surrogate endpoints were conflicting. For 
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example, alkaline phosphatase and bilirubin were deemed as valid in the assessment of 
Obeticholic acid for primary biliary cholangitis e by three agencies (NICE (30), SMC (31), 
CADTH (32)) and invalid by three agencies (HAS (33), IQWiG/G-BA (34), ZIN (35)). 
Level of evidence 
The acceptability of the putative surrogate measure should be based on the related level of 
evidence (see Table 1). This can be as low as expert opinion, as in the NICE HTA assessment 
of PFS of Brentuximab vedotin in CD30-positive Hodgkin lymphoma (36), or as high as 
individual-patient data meta-analyses of RCTs, as seen in the evaluation of pathological 
complete response of Pertuzumab in HER2-+ breast cancer (37). However, a higher level of 
evidence does did not always mean result in a positive opinion expressed by the committee in 
relation to the acceptability of the surrogate. For example, based on the Collaborative
Trials in Neoadjuvant Breast Cancer pooled individual-patient data meta-analysis, CADTH 
concluded, (38), that there is insufficient evidence to support the validity of pathological 
complete response as a surrogate for long-term outcomes in breast cancer (39). In contrast, 
informed by clinicians’ opinion, NICE accepted PFS for Brentuximab vedotin in CD30-
positive Hodgkin lymphoma (36).
Strength of association
Whilst Rreports often discussed the concept of association or correlation between the two 
endpoints of interest but rarely reported an actual metric (e.g., R2, Spearman’s ρ correlation 
coefficient). For example, the Pirfenidone in idiopathic pulmonary fibrosis appraisal by NICE 
(40) cited one study showing that there is a moderate correlation between changes in percent 
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predicted forced vital capacity and changes in a disease specific health-related quality of life 
measure (i.e., Spearman’s ρ correlation coefficient of -0.32). Lack of reporting of correlation 
metrics may reflect the difficult interpretation of these values, limited methods guidance, or 
presumed confidence in the validity of the surrogate. 
Quantification of effect on patient-relevant outcomes
Quantification of the expected treatment effect on the patient-centered outcome based on the 
observed effect on the surrogate endpoint was rarely reported. In some cases this 
quantification was a risk equation based on previous longitudinal studies or registries in the 
same (or similar) therapy area. In the appraisal of Evolocumab in primary 
hypercholesterolaemia/mixed dyslipidaemia, treatment effects were modelled with published 
risk equations from the Framingham Heart Study and the UK REACH registry for 
cardiovascular disease patients (41). The surrogate threshold effect (STE) has been proposed 
as key metric to identify the minimum level of observed effect on the surrogate endpoint in 
order to predict a significant effect on the patient-centered outcome (42). However, STE was 
only reported by IQWIG report on Ribociclib in locally advanced or metastatic breast cancer 
(43). 
Use of surrogate endpoint evidence in cost-effectiveness models
For those reports that included a cost-effectiveness analysis, surrogate endpoints were usually 
a key input in the decision model. For example, annual change in total kidney volume was 
used as an intermediate step to model change in estimated glomerular filtration rate (eGFR) 
in the cost-effectiveness model of Tolvaptan in autosomal dominant polycystic kidney 
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disease (44). Whilst quantification of the treatment effect on the final outcome based on the 
surrogate could be an output of the decision model, we did not find any examples of this 
across reports in this study. Despite a pivotal trial powered for a surrogate primary endpoint, 
the available cost-effectiveness models were developed using immature survival data from 
short-term studies extrapolated to obtain estimates of the full survival benefit (45, 46). 
Evidence around the validation of the primary surrogate endpoint could inform the choice of 
the methods for performing the extrapolation in economic models (e.g., how plausible the 
extrapolated portions are), (47) but we never encountered this across our sample of HTA 
reports.
Whilst surrogate endpoints are generally assumed to replace for patient-relevant outcomes, 
such as overall survival, in cost-effectiveness models they may also be used to predict  for 
health related quality of life. (e.g.For example, a key utility value was an assumed 0.04 
increase in health-related quality of life for patients experiencing a sustained virologic 
response with the use of Ledipasvir–Sofosbuvir drug combination in chronic hepatitis C 
evaluation.) (48); They may also or be used to predict healthcare resource consumption/costs 
(e.g. progression free survival  as a proxy for time on treatment with biologic Cobimetinib for 
the management of unresectable or metastatic melanoma) (49).
Multivariable regression analysis showed that reporting about the level of evidence 
supporting the relationship between the putative surrogate and the patient-centered endpoint 
of interest, increased the probability of accepting the validity of the surrogate endpoints (odds 
ratio: 4.60, 95% CI: 1.60 to 13.18, p  = 0.005), regardless as to whether this evidence is 
biological, plausibility anecdotal, observational. or experimental (Table 4). That these other 
elements are statistically significant in univariate regressions suggests that they are correlated 
with reporting of evidence. 
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Table 4 Factors associated with surrogate acceptability and recommendation given
What impact does use of surrogate endpoints have on the recommendations given?
We were able to examine the recommendations based on 113 assessments (11 (9%) HTA 
recommendations given by NIPH were not publicly accessible) (Table 2). Pairwise kappa 
coefficients show at least modest (>0.20) agreement on the final recommendation given by 
IQWiG/G-BA and SMC and  substantial (>0.60) agreement on the final recommendation 
given by IQWiG/G-BA and HAS. Overall, the level of agreement across the eight agencies 
was relatively low (0.18, p = 0.004) (Supplementary Table 3).
For eight (6%) of the recommendations, orphan drug designation was associated to with 
either full approval (n = 6) or restricted approval (n = 2). A patient access scheme was 
mandated in 19 (16%) of the restricted recommendations by NICE and SMC, with risk-
sharing agreements being required in 3 (2%) of these restricted recommendations. In 10 (8%) 
of the restricted recommendations, a price reduction was required. Lack of benefit, high 
uncertainty on outcomes, or insufficient evidence on the relationship between the surrogate 
and patient-relevant outcomes was explicitly cited in 13 (11%) rejections. In contrast, 6 (5%) 
approval recommendations were made despite stated uncertainty in clinical or cost-
effectiveness evidence (Supplementary Table 4). 
With the exception of orphan status (odds ratio 8.61, 95% 1.03 - 72.94, p = 0.047), none of 
the other factors were predictive of the final coverage recommendation (Table 4).
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Discussion
In this study we mapped the methods used to deal with in 124 surrogate endpoint-
basedsubmissions across 124  HTA evaluations/reports on 23 different health technologies 
across eight HTA agencies. Based on a previously proposed three-step framework previously 
proposed for the validation of surrogate outcomes (15), we found that 61 (49%) of the reports 
discussed the level of evidence to support the relationship between the putative surrogate 
endpoint and the patient-centered outcome based on a IPD individual participant meta-
analyses of randomised controlled trials in the relevant indication. Only 27 (22%) evaluations 
reported a correlation coefficient or other association measure. When these were available, 
these associations were usually below low compared to recommended thresholds for 
acceptability of surrogate in this field (e.g., The independent Institute for Quality and 
Efficiency in Health Care (IQWiG) in Germany recommend a high correlation is achieved 
i.e., when the lower limit of the 95% confidence interval for R  0·85 recommended by 
IQWiG) (50). In 40Forty (32%) reports, analysts reports  tried to quantifiedy the expected 
effect on the patient-centered outcome given the observed effect on the surrogate outcome. A 
clear statement around the acceptability of the surrogate endpoint was provided in 49 (40%) 
reports, whilst 23 (19%) rejected refused the validity of the putative proposed surrogate 
endpoints. Our regression models showed that searching for evidence of about the 
relationship between the surrogate and patient-centered outcome was to be a predictor of the 
HTA agency’s acceptacceptance ability of the putative surrogate endpoint but did not show 
any significant effect for the other steps in the validation process. 
We also investigated the impact on the surrogate validation process on the coverage 
recommendation. Among the 113 assessments with a policy recommendation, 32 (28%) 
technologies were fully approved, 20 (18%) were rejected, and 61 (54%) received restricted 
approval. To deal with the To handle the decision uncertainty in these appraisals as the result 
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of the use surrogate endpoints, HTA agencies often used conditional approval based on price 
discount agreements (including patient access and risk-sharing schemes with evidence 
development), restricted indications, or to the applied cation of a more permissive evaluation 
frameworks (such as orphan technology designation process, end-of-life treatment, or 
specialist  coverage oncology programmes, such as the Cancer Drugs Fund in the UK). For 
example, when evaluating Bosutinib, all HTA agencies had access to results of the main 
study that reported major cytogenetic response and immature overall survival data. IQWiG 
approved Bosutinib as an orphan medicine despite concluding that major cytogenetic 
response and overall survival was limited.. Scottish Medicine Consortium also found ‘high 
uncertainty around the survival estimate’ but and still approved Bosutinib as part of the ultra-
orphan process. Whilst the reimbursement of drugs authorized with orphan designation may 
vary across Europe, orphan status is usually an policy imperative that commits HTA agencies 
to recommend even without evidence of additional benefit (51). We found weak evidence 
that the acceptability of the surrogate endpoint was associated with the final coverage 
decision made by HTA agencies. 
We found considerable variability in the level of scrutiny applied with respect to the 
surrogacy issue across HTA agencies. This variability is in part explained by differences in 
the methodological guidelines followed by the HTA agencies (7). Different expertise 
available to the committee, different level of reporting, or different interpretations of the 
definition of surrogate endpoints may also play a role. Some surrogate endpoints, especially 
so-called intermediate endpoints (e.g., progression free survival, disease free survival, event 
free survival), may not be considered not to require in need of further validation by HTA 
agencies as given that they have been already accepted by a regulatory body for marketing 
authorization. In several cases, HTA agencyie’s explicitly quoted EMA European Medicines 
Agency or US FDA Food and Drug Agency approval documents to support their acceptance 
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bility of the validity of a the surrogate endpoint. However, it is important to recognise that the 
mandate of regulators is not the same as HTA organizations . in (19). The underlying 
evidence for the accepted surrogate endpoints for regulatory review may be weak or missing 
(52, 53). As a lifecycle evaluation to healthcare technologies has become more widespread, 
regulatory agencies have gained statutory authority to order post-marketing studies, typically 
in the case of approvals based on uncertain evidence. However, only 1 in 10 of new drug 
indications approved by the US Food and Drug AgencyFDA on the basis of surrogate 
endpoints markers of disease have been shown to have at least one post-approval trial 
validating the use of the surrogate marker or demonstrating improved overall survival (54, 
55, 56).
Surrogate endpoint evidence impacts may influence both the assessment of clinical and cost-
effectiveness of a health technology (7). However,  It was common in the we found limited 
consideration in the  economic elements of the HTA reports included in this study . this study 
to find For example, some cost-effectiveness models were based on developed around 
extrapolations of immature survival data from short-term studies rather than use of that 
extrapolated secondary endpoints over the lifetime horizon of the model without considering 
validated ion of the primary surrogate endpoint data. Furthermore, . Moreover, there was 
little use of biomarkers or intermediate endpoints as replacements for either health-related 
quality of life or healthcare resource consumption/costs.  is often not supported by high 
quality evidence. 
Limitations
Our analyses were limited to consideration of publicly available information and reporting 
detail varied greatly between agencies. As we based our initial selection of technologies on 
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which National Institute for Health and Care (a text search for surrogacy terms of NICE) 
reports that explicitly mentioned surrogacy related terms, it is possible we many have 
excluded that some of the report/technologies that excluded from our sample may in fact 
have also included using surrogate endpoint evidence. We cannot exclude the possibility that 
considerationsissue of surrogacy issues occurred during HTA committee meetings but that 
these observations were not reported in public documents. Some of the non-English reports 
were not double screened due to lack of language expertise across the co-authors. Although 
we were to only identifiedy only two non-drug pharmaceutical technologies in on our sample, 
we believe that the findings of report apply equally to such technologies, including medical 
devices non-drug as drug technologies.
Conclusions 
We found that the hHandling of surrogate endpoints evidence in evaluation reports varied 
greatly across HTA reports and HTA agencies, with inconsistent consideration of level of 
evidence and statistical validation. Considerationing of the level of evidence supporting the 
relationship between the surrogate endpoint and patient-centre outcome cy relationship 
increased the likelihood of acceptability of a surrogate endpoint. However, , but we did not 
find strong evidence supporting the an association between accepting the ance of surrogate 
endpoint validation methods and the coverage recommendation made about the treatment. 
The cClaims of surrogate validity needs to be considered in the contextcontextually, given 
that the relationship between surrogate endpoint and patient-relevant outcome are is typically 
treatment- and indication- specific. 
HTA evaluation reports often refer to regulatory (FDA or EMA) statements about the 
acceptability of surrogate endpoints. However, regulators are typically more focused on 
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safety and shorter-term efficacy, and registration trials are often specifically designed to 
answer these questions. In contrast,Given that  HTA agencies focus on a longer-term 
perspective and seek to assess clinical effectiveness and cost-effectiveness, their 
considerations on the acceptability of surrogate endpoints may differ to those of regulators 
(57).  
Our findings call demonstrate the need for further consideration of the issue of surrogacy and 
the need for harmonization of practices between regulatory and HTA agencies and across 
international jurisdictions.
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